<div class="title">AOP 440: Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</div>
<strong>Short Title: Hypothalamic estrogen receptors inhibition leading to ovarian cancer</strong>
<td>Under development: Not open for comment. Do not cite</td>
<td>Under Development</td>
<td>1.104</td>
<td>Included in OECD Work Plan</td>
</tr>
</tbody>
</table>
</div>
</div>
<div id="coaches">
<h2>Coaches</h2>
<ul>
<li class="contributor" id="coach_63">
Rex FitzGerald
</li>
</ul>
</div>
<div id="abstract">
<h2>Abstract</h2>
<p style="margin-left:18px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Malfunctioning of sex hormones (e.g., estradiol, estrone and progesterone) may result in ovarian cancer </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Fooladi et al. 2020, Meehan and Sadar 2003)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Exposure to endocrine-disrupting chemicals (EDCs) in the form of occupational usage of pesticides, fungicides, herbicides, plasticizers, cosmetics, etc. are the causes of ovarian cancer </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Samtani, Sharma and Garg 2018)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Some stressors molecules (e.g., clomiphene citrate, </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Tamoxifen, Toremifene</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">) act on neuronal cell in the hypothalamus (molecular initiating event, MIE), where they inhibit hypothalamic Estrogen Receptors selectively and these chemicals increase the risk of ovarian cancer </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(McLemore et al. 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. These </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">stressors molecules stimulate the releasing of gonadotropin-releasing hormone (GnRH) from hypothalamic region of brain by the suppression of hypothalamic Estrogen Receptors. Subsequently, secretion of luteinizing hormone (LH) from pituitary becomes high</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Cassidenti et al. 1992, Mungenast and Thalhammer 2014a, Tomao et al. 2014)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. This hormone regulates the synthesis of sex hormones (e.g., estrogens) at cellular level </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Shoemaker et al. 2010a, Tomao et al. 2014)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. These sex hormones are primarily produced in the gonads through a series of enzyme-mediated reactions from cholesterol (precursor) and control through complex signalling pathway along hypothalamus – pituitary – gonadal (HPG) axis </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Shoemaker et al. 2010a, Perkins et al. 2019)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. High estrogen level increases the risk of ovarian cancer </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">via ovarian epithelial cell hyperplasia</span></span> <span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(McLemore et al. 2009, Tomao et al. 2014)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">.</span></span></span></span></p>
</div>
<div id="background">
<h3>Background</h3>
<p style="margin-left:18px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Development and progression of certain types of cancer disease (e.g. ovarian cancer, breast cancer, prostate cancer etc.) is related with the hormonal levels in human. Lack of proper diagnosis at early stage of the disease increase the mortality rate of the cancer. Among many types of cancer ovarian cancer has the high mortality rate (~50%) due to the lack of proper diagnosis at early stage of the disease progression. Circulating levels of the steroidal sex hormones in conjunction with the gene expression is related with the progression of this disease. Some important sex hormones which are related with many cancer diseases include oestrogen, progesterone and testosterone. Oestrogen hormone mainly involved in female sex organ development, controlling of menstruation cycle etc. Progesterone also involved in controlling menstrual cycle, maintaining pregnancy and spermatogenesis. Testosterone hormone regulates sexual development, bone mass development, red blood cell production in male. </span></span></span></span></p>
<h2>AOP Development Strategy</h2>
<div id="context">
<h3>Context</h3>
<p style="margin-left:18px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Development and progression of certain types of cancer disease (e.g. ovarian cancer, breast cancer, prostate cancer etc.) is related with the hormonal levels in human. Lack of proper diagnosis at early stage of the disease increase the mortality rate of the cancer. Among many types of cancer ovarian cancer has the high mortality rate (~50%) due to the lack of proper diagnosis at early stage of the disease progression. Circulating levels of the steroidal sex hormones in conjunction with the gene expression is related with the progression of this disease. Some important sex hormones which are related with many cancer diseases include oestrogen, progesterone and testosterone. Oestrogen hormone mainly involved in female sex organ development, controlling of menstruation cycle etc. Progesterone also involved in controlling menstrual cycle, maintaining pregnancy and spermatogenesis. Testosterone hormone regulates sexual development, bone mass development, red blood cell production in male. </span></span></span></span></p>
</div>
</div>
<div id="development_strategy">
<h3>Strategy</h3>
<p style="margin-left:18px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">In females, sexual hormone balance protects the ovaries from the tumor development. A number of researches revealed that molecular level perturbation leading towards sex hormone imbalance plays important role in the development of the ovarian cancer. Specifically, high level of estrogens (estradiol, estrone and progesterone) enhances the risk of ovarian cancer via ovarian epithelial cell hyperplasia. Estrones are regulated in hypothalamus and activity of estrogen receptors plays crucial role. Research reports reveled that suppression of the activity of estrogen receptors, leads to high level of estrogens in blood circulation via </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">hypothalamus – pituitary – gonadal (HPG) axis. Therefore, suppression of the </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">activity of estrogen receptors is considered as molecular initiating event (MIE). This MIE regulates several Key Events (Kes) along HPG axis for high level of estrogens in circulating blood that increases the risk of ovarian cancer via ovarian epithelial cell hyperplasia.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><strong><em><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Suppression, Estrogen receptor (ER) activity [Evidence- Strong]: </span></span></em></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">There are number of reports available related to suppression of Estrogen receptor activity (ER) </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Baez-Jurado et al., 2018; Cosman, 2003; Haskell, 2003; Ng et al., 2009; Kang et al., 2001; Roy et al., 1999; Marques P, 2018; Mungenast and Thalhammer, 2014b; Ghasemnejad-Berenji et al., 2020; J. H. Liu, 2020; Oride et al., 2020; Zhang et al., 2020; John F. Kerin et al., 1985b; The Practice Committee of the American Society for Reproductive Medicine, 2013; Moskovic et al., 2012 ; Bryan J. Herzog, 2020)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Stressors act on neuronal cell in the hypothalamus, where it inhibits hypothalamic Estrogen Receptors selectively. A number of compounds or molecules (e.g. Clomiphene citrate, Tamoxifen, Toremifene etc.) are detected which show the modulation activity of estrogen receptor in brain leading to high GnRH pulses </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Haskell, 2003; Cosman, 2003)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><strong><em><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Increased, secretion of GnRH from hypothalamus[Evidence- Strong]: </span></span></em></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">A number of evidencesare found by the researchesthat the increased secretion of </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">gonadotropin-releasing hormone (GnRH)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Shander and Goldman, 1978; Tsourdi et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Studies had shown that of inhibition of Estrogen receptor activity (ER) enhances the secretion of GnRH in human </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Adashi et al., 1980; Bussenot et al., 1990; JOHN F KERIN et al., 1985a; Tan et al., 1996)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">, rat and mice </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Bharti et al., 2013; Kumar and Pakrasi, 1995; Zoeller and Young, 1988)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Studies on human patient had shown the application of clomiphene is able to promote response of GnRH secretion </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Goerzen et al., 1985; Tan et al., 1996)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><strong><em><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Increased, secretion of LH from anterior pituitary [Evidence- Strong]: </span></span></em></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Good evidence may be acquired from different published articles for the increased secretion of LH increases from anterior pituitary </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Plouffe and Siddhanti, 2001; Wright et al., 2012; Shoemaker et al., 2010b)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. It is also reported that increased secretion of the GnRH in hypothalamus leads to high levelofLH in human </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(John F Kerin et al., 1985a; Adashi et al., 1980; Bussenot et al., 1990)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">, mice/rat.</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Bharti et al., 2013; Kumar and Pakrasi, 1995; Botte et al., 1999)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> and cow </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Fields et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><strong><em><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Increased, Steroidogenic acute regulatory protein (StAR) [Evidence- Strong]: </span></span></em></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Steroidogenic acute regulatory protein (StAR) plays critical role in luteal steroidogenesis by controlling the transport of cholesterol from the outer to inner mitochondrial membrane</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Wu et al., 2003; Shoemaker et al., 2010b)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.It had been reported that increase in LH level leads to increase StAR protein concentration in human</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Tsang et al., 1980; Johnson and Bridgham, 2001; Murayama et al., 2012; Rekawiecki et al., 2005)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">, rat</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(T. Liu et al., 2007; Martinat et al., 2005)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> and mice</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Eacker et al., 2008; Tsuchiya et al., 2003)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><strong><em><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Increased, estrogens [Evidence- Strong]: </span></span></em></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Aromatase is a key enzyme for estrogen formation in human tissues. In female, one of the important sites of estrogen enzyme synthesis is ovarian granulose cells</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Holesh et al., 2017; Shoemaker et al., 2010b)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Although ovarian aromatase enzyme expression in postmenopausal female is very low, high estrogen level is maintained in the blood through aromatase expression in other tissues. A number of researches had shown increased synthesis of StAR Protein increases the estrogen in ovarian granulosa cellsin human </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Kiriakidou et al., 1996; Fang et al., 2016; Men et al., 2017)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">, rat </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Ronen-Fuhrmann et al., 1998; Nimrod, 1981)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> and fish </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Kusakabe et al., 2002)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><strong><em><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Increased, circulating estrogen levels [Evidence- Strong]: </span></span></em></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Researches had shown increased synthesis of estrogen in ovarian granulosa cells leads to maintain the high circulating estrogen levels in blood </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Holesh et al., 2017; Shoemaker et al., 2010b)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><strong><em><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Hyperplasia, ovarian epithelium [Evidence- High]: </span></span></em></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Ovarian surface is covered by the epithelium cells often called as ovarian mesothelium tissue. High evidence is available which supports that hyperplasia of the stromal cells might lead towards the hyperplasia of the ovarian epithelium tissue</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Nyboe Andersen et al., 2008; Kang et al., 2001)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><strong><em><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Promotion, ovarian adenomas[Evidence- Moderate]: </span></span></em></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Ovarian adenoma or cystadenoma is classified as benign tumor in the epithelial tissue. Evidence on the promotion of ovarian adenoma due to the hyperplasia in the ovarian epithelial tissue is available. </span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,sans-serif"><strong><em><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif"><span style="color:black">Promotion, ovarian cancer [Evidence- Strong]: </span></span></span></em></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif"><span style="color:black">Promotion of ovarian adenomas leads to the phenotype outcome of ovarian cancer at individual level </span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif"><span style="color:black">(Johansson et al., 2022, Christine Stewart et al., 2019)</span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif"><span style="color:black">.</span></span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Sex: </span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">This particular AOP is mainly applicable for the females. Sex hormone regulation in female is more complex compare to the male. Development and growth of the ovaries depend on the hormonal balance in the body. This hormonal balance in female changes often observed during the menstrual cycle and pregnancy. Imbalance in the hormonal levels leads to the abnormal function of the ovaries.Predominant form of estrogen (estradiol) hormone also found in male and plays critical role in sexual behavior and spermatogenesis. However, males more likely experiences imbalance in testosterone hormonelevels.</span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Life stage: </span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">This AOP is closer to the adult female. In particular the females (at the age of 45-55) going through the menopause are having greater chance of developing ovarian cancer compared to the young adult female. Young female undergoing through the hormonal therapy (usually estrogen) also having high risk of developing ovarian cancer. Risk factor of ovarian cancer is high in case of adult females who are taking ovulation stimulating drugs to increase fertility. </span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Taxonomic: </span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">For this AOP taxonomic domain is applicable to the different species like mice, rat, guinea pig and human.</span></span></span></span></span></p>
<h3>Essentiality of the Key Events</h3>
<p><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">In this AOP the essentiality of the proposed events are supported by a number of scientific works. </span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kettel et al., had shown the treatment of seventeen females with clomiphene citrate with 150mg/day dose for 5 days enhance the estrogen levels. Analysis of the other hormones (follicle-stimulating hormone, luteinizing hormone, gonadotropin-releasing hormone) levels suggest the clomiphene citrate involved in the modulation in hormonal secretion at the hypothalamic site </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Kettel et al., 1993)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Koch et al, had shown female rat injected with the clomiphene citrate (1-100 ng/kg) for 20 days increase the gonadotropin-releasing hormone (GnRH) release in the hypothalamus region </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Koch et al., 1971)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Research by Kurosawa et al., on 293T cells (transfectable derivative of human embryonic kidney 293 cells, revealed that effect of clomiphene citrate depend on the concentration of the molecule. Clomiphene citrate at higher concentration (10<sup>-10</sup> - 10<sup>-12</sup> M) showed the estrogenic activity. However at higher concentration (10<sup>-6</sup> - 10<sup>-12</sup> M) no estrogenic activity was observed. Results of the study also suggest that clomiphene citrate either act as agonist or as an antagonist depends on the presence of 17β-estradiol (E2) receptor</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Kurosawa et al., 2010)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></span></p>
<h3>Weight of Evidence Summary</h3>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Overall assessment of the biological plausibility, empirical support and quantitative understanding of the KEs and KERs associated with this AOP shows that molecular mechanism or signaling pathway of tumor development in the female ovaries due to the suppression of estrogen receptors activities in the hypothalamus is still unclear. </span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Empirical evidence is available which shows the release of gonadotropin-releasing hormone (GnRH) depends on the concentration of the Selective Estrogen Receptors Modulator (SERM) compound (e.g. clomiphene citrate). However, molecular mechanism for the enhancement of GnRH by suppression of Estrogen receptor activity is poorly known.A number of researches had shown secretion of luteinizing hormone (LH) from anterior pituitary depends on the GnRH concentration or dose. Scientific reports have shown the both stimulatory and inhibitory effects on the GnRH secretion exhibited by the estradiol depending on the concentration of stressor (clomiphene) molecules and presence of types of receptors. The requirement of the GnRH dose for the secretary release of the LH in the different species varies widely. </span></span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">A number of articles had shown that release of LH from the anterior pituitary regulates the steroidogenic function of cells by controlling the cholesterol transportation to the mitochondria. Biological plausibility of this event is very high as a number of studies have shown the similar results using different biological models (e.g. granulosa cells of adult female, bovine luteal cells, leydig cells of mice and rat etc.) in their study. Estradiol synthesis during menstrual cycle is governed via expression of StAR protein synthesis. Quantitative estimation of the event has been performed through indirect measurement (e.g. Northern blot analysis of mRNA collected from ovarian follicle granulosa cells). Therefore in many studies finding results are inconsistent. Circulating estrogen levels increases due to the increased estradiol synthesis and concentration controlled by the negative feedback loop of the other steroidal hormone synthesis.Biological evidence of tumor formation in the ovarian granulose cells due to the high circulating estrogen levels in the plasma is pretty high. High circulating estrogen drives the endometrial hyperplasia towards the progression of endometrial cancer.</span></span></span></span></span></p>
<h3>Quantitative Consideration</h3>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Quantitative understanding in many KEs and KERs are available. However, exploitation of different biological models and use of different assay techniques provide incoherent results. Inconsistent results also have been mentioned in many KEs and KERs. A few assay techniques such as radioimmunoassay, radioreceptor assay, estrogen receptor binding assay etc. are sensitive enough to measure the concentration of a molecule at pictogram level. Some other techniques such as quantitative real time PCR (qRT-PCR), northern blot analysis of RNA also have been used for quantitative estimation of molecules at low concentration. Some indirect methods such as immunohistochemistry also have been employed for identification and quantitative estimation of biological molecule.</span></span></span></span></span></p>
<h2>Considerations for Potential Applications of the AOP (optional)</h2>
<p style="text-align:justify"><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif"><span style="color:black">This AOP provides the valuable informations regarding chemical messengers and different glands of endocrine system that are related for the risk and promotion of ovarian cancer. Linkage of qualitative and quantitative informations of different chemical messengers for the promotion of ovarian cancer would be beneficial for the cancer therapy and cancer drug development. Further, this </span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif"><span style="color:black">AOP</span></span></span> <span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif"><span style="color:black">would</span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif"><span style="color:black"> be helpful to evaluate the hazardous long-term effects of the endocrine-disrupting chemicals and drugs which may lead towards the development of the ovarian cancer. This AOP would also help to regulate the uses of these stressor molecules which have inhibitory effects on the </span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif"><span style="color:black">hypothalamic Estrogen Receptors.</span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif"><span style="color:black"> Understanding of the molecular events related with this AOP would help to screen these molecules and provide guideline to access the risk associated with these stressors.</span></span></span></span></span></span></p>
</div>
<div id="references">
<h2>References</h2>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Adashi, E., A. Hsueh & S. Yen (1980) Alterations induced by clomiphene in the concentrations of oestrogen receptors in the uterus, pituitary gland and hypothalamus of female rats. <em>Journal of Endocrinology,</em> 87<strong>,</strong> 383-392.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Baez-Jurado, E., M. A. Rincon-Benavides, O. Hidalgo-Lanussa, G. Guio-Vega, G. M. Ashraf, A. Sahebkar, V. Echeverria, L. M. Garcia-Segura & G. E. Barreto (2018) Molecular mechanisms involved in the protective actions of Selective Estrogen Receptor Modulators in brain cells. <em>Front Neuroendocrinol,</em> 52<strong>,</strong> 44-64.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Bharti, S., M. Misro & U. Rai (2013) Clomiphene citrate potentiates the adverse effects of estrogen on rat testis and down-regulates the expression of steroidogenic enzyme genes. <em>Fertility and sterility,</em> 99<strong>,</strong> 140-148. e5.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Botte, M., Y. Lerrant, A. Lozach, A. Berault, R. Counis & M. Kottler (1999) LH down-regulates gonadotropin-releasing hormone (GnRH) receptor, but not GnRH, mRNA levels in the rat testis. <em>Journal of Endocrinology,</em> 162<strong>,</strong> 409-415.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Bryan J. Herzog, H. M. T. N., Ayman Soubra, and Wayne J.G. Hellstrom (2020) Clomiphene Citrate for Male Hypogonadism and Infertility: An Updated Review. <em>Androgens: Clinical Research and Therapeutics,</em> 1<strong>,</strong> 62-69.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Bussenot, I., J. Parinaud, C. Clamagirand, G. Vieitez & G. Pontonnier (1990) Effect of clomiphene cirate on oestrogen secretion by human granulosa cells in culture. <em>Human Reproduction,</em> 5<strong>,</strong> 533-536.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Cassidenti, D. L., R. J. Paulson, R. A. Lobo & M. V. Sauer (1992) The synergistic effects of clomiphene citrate and human menopausal gonadotrophin in the folliculogenesis of stimulated cycles as assessed by the gonadotrophin-releasing hormone antagonist Nal-Glu. <em>Hum Reprod,</em> 7<strong>,</strong> 344-8.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Christine Stewart, Christine Ralyea & S. Lockwood (2019) Ovarian Cancer: An Integrated Review. <em>Seminars in Oncology Nursing,</em> 35<strong>,</strong> 151-156.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Eacker, S. M., N. Agrawal, K. Qian, H. L. Dichek, E. Y. Gong, K. Lee & R. E. Braun (2008) Hormonal regulation of testicular steroid and cholesterol homeostasis. <em>Mol Endocrinol,</em> 22<strong>,</strong> 623-35.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Fang, L., Y. Yu, R. Zhang, J. He & Y. P. Sun (2016) Amphiregulin mediates hCG-induced StAR expression and progesterone production in human granulosa cells. <em>Sci Rep,</em> 6<strong>,</strong> 24917.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Fields, S. D., B. L. Perry & G. A. Perry (2009) Effects of GnRH treatment on initiation of pulses of LH, LH release, and subsequent concentrations of progesterone. <em>Domest Anim Endocrinol,</em> 37<strong>,</strong> 189-95.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Fooladi, S., H. Akbari, M. Abolhassani, E. Sadeghi & H. Fallah (2020) Estradiol, des-acylated, and total ghrelin levels might be associated with epithelial ovarian cancer in postmenopausal women. <em>medRxiv</em>.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Ghasemnejad-Berenji, M., S. Pashapour & H. Ghasemnejad-Berenji (2020) Therapeutic potential for clomiphene, a selective estrogen receptor modulator, in the treatment of COVID-19. <em>Medical Hypotheses,</em> 145.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Goerzen, J., B. Corenblum & P. J. Taylor (1985) Potentiation of GnRH response by clomiphene citrate. <em>J Reprod Med,</em> 30<strong>,</strong> 749-52.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Haskell, S. G. (2003) Selective estrogen receptor modulators. <em>South Med J,</em> 96<strong>,</strong> 469-76.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Holesh, J. E., A. N. Bass & M. Lord (2017) Physiology, Ovulation.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Janson, P. O., L. Hamberger, J. E. Damber, B. Dennefors & F. Knutson (1980) Steroid production in vitro of a hilus cell tumor of the human ovary. <em>Obstet Gynecol,</em> 55<strong>,</strong> 662-5.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Johansson, Å., D. Schmitz, J. Höglund, F. Hadizadeh, T. Karlsson & W. E. Ek (2022) Investigating the Effect of Estradiol Levels on the Risk of Breast, Endometrial, and Ovarian Cancer. <em>J Endocr Soc,</em> 6<strong>,</strong> bvac100.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Johnson, A. L. & J. T. Bridgham (2001) Regulation of steroidogenic acute regulatory protein and luteinizing hormone receptor messenger ribonucleic acid in hen granulosa cells. <em>Endocrinology,</em> 142<strong>,</strong> 3116-24.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Kang, S. K., K. C. Choi, C. J. Tai, N. Auersperg & P. C. Leung (2001) Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. <em>Endocrinology. 2001 Feb;142(2):580-8. doi: 10.1210/endo.142.2.7982.</em></span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Kerin, J. F., J. H. Liu, G. Phillipou & S. Yen (1985a) Evidence for a hypothalamic site of action of clomiphene citrate in women. <em>The Journal of Clinical Endocrinology & Metabolism,</em> 61<strong>,</strong> 265-268.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Kerin, J. F., J. H. Liu, G. Phillipou & S. S. C. Yen (1985b) Evidence for a Hypothalamic Site of Action of Clomiphene Citrate in Women. <em>The Journal of Clinical Endocrinology & Metabolism,</em> 61<strong>,</strong> 265-268.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Kettel, L. M., S. J. Roseff, S. L. Berga, J. F. Mortola & S. S. Yen (1993) Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. <em>Fertil Steril. ,</em> 59<strong>,</strong> 532-38.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Kiriakidou, M., J. M. Mcallister, T. Sugawara & J. Strauss 3rd (1996) Expression of steroidogenic acute regulatory protein (StAR) in the human ovary. <em>The Journal of Clinical Endocrinology & Metabolism,</em> 81<strong>,</strong> 4122-4128.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Koch, Y., S. Dikstein, E. Superstine & F. G. Sulman (1971) THE EFFECT OF PROMETHAZINE AND CLOMIPHENE ON GONADOTROPHIN SECRETION IN THE RAT. <em>Journal of Endocrinology,</em> 49<strong>,</strong> 13-17.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Kumar, A. & P. L. Pakrasi (1995) Estrogenic and antiestrogenic properties of clomiphene citrate in laboratory mice. <em>Journal of Biosciences,</em> 20<strong>,</strong> 665-673.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Kurosawa, T., H. Hiroi, M. Momoeda, S. Inoue & Y. Taketani (2010) Clomiphene citrate elicits estrogen agonistic/antagonistic effects differentially via estrogen receptors alpha and beta. <em>Endocr J,</em> 57<strong>,</strong> 517-21.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Kusakabe, M., T. Todo, H. J. McQuillan, F. W. Goetz & G. Young (2002) Characterization and expression of steroidogenic acute regulatory protein and MLN64 cDNAs in trout. <em>Endocrinology,</em> 143<strong>,</strong> 2062-70.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Liu, J. H. (2020) Selective estrogen receptor modulators (SERMS): keys to understanding their function. <em>Menopause-the Journal of the North American Menopause Society,</em> 27<strong>,</strong> 1171-1176.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Liu, T., J. Wimalasena, R. L. Bowen & C. S. Atwood (2007) Luteinizing hormone receptor mediates neuronal pregnenolone production via up-regulation of steroidogenic acute regulatory protein expression. <em>J Neurochem. ,</em> 100<strong>,</strong> 1329-39.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Marques P, S. K., George JT, et al. (2018) Physiology of GNRH and Gonadotropin Secretion. [Updated 2018 Jun 19].<em> Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK279070/" style="color:blue; text-decoration:underline">https://www.ncbi.nlm.nih.gov/books/NBK279070/</a></em>.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Martinat, N., P. Crepieux, E. Reiter & F. Guillou (2005) Extracellular signal-regulated kinases (ERK) 1, 2 are required for luteinizing hormone (LH)-induced steroidogenesis in primary Leydig cells and control steroidogenic acute regulatory (StAR) expression. <em>Reprod Nutr Dev,</em> 45<strong>,</strong> 101-8.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">McLemore, M. R., C. Miaskowski, B. E. Aouizerat, L. M. Chen & M. J. Dodd (2009) Epidemiological and genetic factors associated with ovarian cancer. <em>Cancer Nurs,</em> 32<strong>,</strong> 281-8; quiz 289-90.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Meehan, K. L. & M. D. Sadar (2003) Androgens and androgen receptor in prostate and ovarian malignancies. <em>Front Biosci,</em> 8<strong>,</strong> d780-800.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Men, Y., Y. Fan, Y. Shen, L. Lu & A. N. Kallen (2017) The Steroidogenic Acute Regulatory Protein (StAR) Is Regulated by the H19/let-7 Axis. <em>Endocrinology,</em> 158<strong>,</strong> 402-409.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Moskovic, D. J., D. J. Katz, A. Akhavan, K. Park & J. P. Mulhall (2012 ) Clomiphene citrate is safe and effective for long-term management of hypogonadism. <em>BJU International,</em> 100<strong>,</strong> 1524 - 28.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Mungenast, F. & T. Thalhammer (2014a) Estrogen biosynthesis and action in ovarian cancer. <em>Front Endocrinol (Lausanne),</em> 5<strong>,</strong> 192.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">--- (2014b) Estrogen biosynthesis and action in ovarian cancer. <em>Front Endocrinol (Lausanne). 2014 Nov 12;5:192. doi: 10.3389/fendo.2014.00192. eCollection 2014.</em></span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Murayama, C., H. Miyazaki, A. Miyamoto & T. Shimizu (2012) Luteinizing hormone (LH) regulates production of androstenedione and progesterone via control of histone acetylation of StAR and CYP17 promoters in ovarian theca cells. <em>Mol Cell Endocrinol,</em> 350<strong>,</strong> 1-9.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Ng, Y., A. Wolfe, H. J. Novaira & S. Radovick (2009) Estrogen regulation of gene expression in GnRH neurons. <em>Mol Cell Endocrinol. 2009 May 6;303(1-2):25-33. doi: 10.1016/j.mce.2009.01.016. Epub 2009 Feb 2.</em></span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Nimrod, A. (1981) On the synergistic action of androgen and FSH on progestin secretion by cultured rat granulosa cells: cellular and mitochondrial cholesterol metabolism. <em>Molecular and cellular endocrinology,</em> 21<strong>,</strong> 51-62.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Nyboe Andersen, A., A. Balen, P. Platteau, P. Devroey, L. Helmgaard & J. C. Arce (2008) Predicting the FSH threshold dose in women with WHO Group II anovulatory infertility failing to ovulate or conceive on clomiphene citrate. <em>Hum Reprod. 2008 Jun;23(6):1424-30. doi: 10.1093/humrep/den089. Epub 2008 Mar 26.</em></span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Oride, A., H. Kanasaki, T. Tumurbaatar, T. Zolzaya, H. Okada, T. Hara & S. Kyo (2020) Effects of the Fertility Drugs Clomiphene Citrate and Letrozole on Kiss-1 Expression in Hypothalamic Kiss-1-Expressing Cell Models. <em>Reproductive Sciences,</em> 27<strong>,</strong> 806-814.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Perkins, E. J., K. Gayen, J. E. Shoemaker, P. Antczak, L. Burgoon, F. Falciani, S. Gutsell, G. Hodges, A. Kienzler, D. Knapen, M. McBride, C. Willett, F. J. Doyle & N. Garcia-Reyero (2019) Chemical hazard prediction and hypothesis testing using quantitative adverse outcome pathways. <em>ALTEX,</em> 36<strong>,</strong> 91-102.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Plouffe, L., Jr. & S. Siddhanti (2001) The effect of selective estrogen receptor modulators on parameters of the hypothalamic-pituitary-gonadal axis. <em>Ann N Y Acad Sci,</em> 949<strong>,</strong> 251-8.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Rekawiecki, R., M. Nowik & J. Kotwica (2005) Stimulatory effect of LH, PGE2 and progesterone on StAR protein, cytochrome P450 cholesterol side chain cleavage and 3beta hydroxysteroid dehydrogenase gene expression in bovine luteal cells. <em>Prostaglandins Other Lipid Mediat,</em> 78<strong>,</strong> 169-84.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Ronen-Fuhrmann, T., R. Timberg, S. R. King, K. H. Hales, D. B. Hales, D. M. Stocco & J. Orly (1998) Spatio-temporal expression patterns of steroidogenic acute regulatory protein (StAR) during follicular development in the rat ovary. <em>Endocrinology,</em> 139<strong>,</strong> 303-15.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Roy, D., N. L. Angelini & D. D. Belsham (1999) Estrogen Directly Represses Gonadotropin-Releasing Hormone (GnRH) Gene Expression in Estrogen Receptor-α (ERα)- and ERβ-Expressing GT1–7 GnRH Neurons1. <em>Endocrinology,</em> 140<strong>,</strong> 5045-5053.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Samtani, R., N. Sharma & D. Garg (2018) Effects of Endocrine-Disrupting Chemicals and Epigenetic Modifications in Ovarian Cancer: A Review. <em>Reprod Sci,</em> 25<strong>,</strong> 7-18.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Scirpa, P., D. Mango, A. Montemurro, F. Battaglia & L. Cantafio (1984) Androstenedione, 17 beta-estradiol and progesterone plasma levels in gonadotropins induction of ovulation. <em>J Endocrinol Invest,</em> 7<strong>,</strong> 357-62.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Shander, D. & B. Goldman (1978) Ovarian steroid modulation of gonadotropin secretion and pituitary responsiveness to luteinizing hormone-releasing hormone in the female hamster. <em>Endocrinology,</em> 103<strong>,</strong> 1383-93.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Shoemaker, J. E., K. Gayen, N. Garcia-Reyero, E. J. Perkins, D. L. Villeneuve, L. Liu & F. J. Doyle (2010a) Fathead minnow steroidogenesis: in silico analyses reveals tradeoffs between nominal target efficacy and robustness to cross-talk. <em>BMC Systems Biology,</em> 4<strong>,</strong> 89.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Shoemaker, J. E., K. Gayen, Natà l. Garcia-Reyero, E. J. Perkins, D. L. Villeneuve, L. Liu & F. J. Doyle (2010b) Fathead minnow steroidogenesis: in silico analyses reveals tradeoffs between nominal target efficacy and robustness to cross-talk. <em>BMC Systems Biology,</em> 4<strong>,</strong> 89.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Tan, S. L., J. Farhi, R. Homburg & H. S. Jacobs (1996) Induction of ovulation in clomiphene-resistant polycystic ovary syndrome with pulsatile GnRH. <em>Obstet Gynecol,</em> 88<strong>,</strong> 221-6.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">The Practice Committee of the American Society for Reproductive Medicine (2013) Use of clomiphene citrate in infertile women: a committee opinion. <em>Fertility and Sterility,</em> 100<strong>,</strong> 341-348.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Tomao, F., G. Lo Russo, G. P. Spinelli, V. Stati, A. A. Prete, N. Prinzi, M. Sinjari, P. Vici, A. Papa, M. S. Chiotti, P. Benedetti Panici & S. Tomao (2014) Fertility drugs, reproductive strategies and ovarian cancer risk. <em>J Ovarian Res,</em> 7<strong>,</strong> 51.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Tsang, B. K., D. T. Armstrong & J. F. Whitfield (1980) Steroid biosynthesis by isolated human ovarian follicular cells in vitro. <em>J Clin Endocrinol Metab. ,</em> 51<strong>,</strong> 1407-11.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Tsourdi, E., A. Kourtis, D. Farmakiotis, I. Katsikis, M. Salmas & D. Panidis (2009) The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. <em>Fertil Steril,</em> 91<strong>,</strong> 1427-30.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Tsuchiya, M., K. Inoue, H. Matsuda, K. Nakamura, T. Mizutani, K. Miyamoto & T. Minegishi (2003) Expression of steroidogenic acute regulatory protein (StAR) and LH receptor in MA-10 cells. <em>Life Sciences,</em> 73<strong>,</strong> 2855-2863.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Wright, D. J., J. N. Earnhardt, R. Perry, S. Bailey, B. Komm, D. R. Minck & M. A. Cukierski (2012) Carcinogenicity and hormone studies with the tissue-selective estrogen receptor modulator bazadoxifene. <em>J Cell Physiol,</em> 228<strong>,</strong> 724-33.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Wu, Q., S. Sucheta, S. Azhar & K. M. Menon (2003) Lipoprotein enhancement of ovarian theca-interstitial cell steroidogenesis: relative contribution of scavenger receptor class B (type I) and adenosine 5'-triphosphate- binding cassette (type A1) transporter in high-density lipoprotein-cholesterol transport and androgen synthesis. <em>Endocrinology,</em> 144<strong>,</strong> 2437-45.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Zhang, Z., J. W. Bartsch, J. Benzel, T. Lei, C. Nimsky & B. Voellger (2020) Selective estrogen receptor modulators decrease invasiveness in pituitary adenoma cell lines AtT-20 and TtT/GF by affecting expression of MMP-14 and ADAM12. <em>Febs Open Bio,</em> 10<strong>,</strong> 2489-2498.</span></span></span></span></p>
<p style="margin-left:9px; text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Zoeller, R. T. & W. S. Young, 3rd (1988) Changes in cellular levels of messenger ribonucleic acid encoding gonadotropin-releasing hormone in the anterior hypothalamus of female rats during the estrous cycle. <em>Endocrinology,</em> 123<strong>,</strong> 1688-9.</span></span></span></span></p>
<td><a href="/aops/165">Aop:165 - Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse</a></td>
<td>KeyEvent</td>
</tr>
<tr>
<td><a href="/aops/440">Aop:440 - Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Clomiphene</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> citrate (a stressor) at 10<sup>-10</sup> - 10<sup>-12</sup> M concentrations exhibits approximately 30% of the estrogenic activity which is same from 17β-estradiol (at 10<sup>-10</sup> M) in ERα-expressing cells where as no activity in ERβ cells. </span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Clomiphene</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> citrate at the concentration of 10<sup>-10</sup> M reveals weak estrogen agonist activity in the presence of 17 β -estradiol (E2) at the concentration of 10<sup>-14</sup> M in ERα-expressing cells, and no activity was found in ERβ cells. </span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Clomiphene</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> citrate at lower doses (10<sup>-10</sup> - 10<sup>-12</sup> M), but not higher doses (10<sup>-6</sup> - 10<sup>-8</sup> M) showed estrogenic activity via ERα. However, </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">clomiphene</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> citrate at concentrations between 10<sup>-6</sup> M and 10<sup>-12</sup> M did not reveal any estrogenic activity via ERβ. In the presence of E2, c</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">lomiphene</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> citrate worked as either as an agonist or an antagonist through ERα depending on the concentrations of E2. </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Clomiphene</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> citrate worked as antagonistic when it is combined with the higher E2 concentrations and worked as agonistic with the lower E2 concentrations. On the other hand, via ER β, clomiphene citrate acted as an estrogen antagonist irrespective of the concentration of E2. </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Kurosawa et al., 2010)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Neuronal cell in Hypothalamus</span></span></span></span></p>
<h4>Key Event Description</h4>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Estrogen receptors are produced in all vertebrates and located in either the cell cytoplasm or nucleus</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Bondesson et al., 2015; Eick and Thornton, 2011)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Estrogen receptors are localized either in cytoplasm, or on the cell surface.</span></span></p>
<p> </p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Site of action:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> Stressors (e.g., clomiphene) act on neuronal cell in the hypothalamus, where it inhibits hypothalamic Estrogen Receptors selectively.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Responses at the macromolecular level:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> Stressors activate the Estrogen Receptor α in the presence of lower level of estrogen and partially blocks the same for higher level of estrogen and works as antagonist for the Estrogen Receptor β</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Trost and Khera, 2014)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Stressors appear to act in the brain's pituitary gland to secrete an increased amount of gonadotropins hormone (GnRH) in hypothalamus leading towards increased GnRH level in blood. </span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Estrogen Receptor α:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> ERα (Estrogen Receptor α or NR3A1 or ESR1) - A nuclear receptor and it is activated by the estrogen (sex hormone). Estrogen located at chromosome number 6 ( 6q25.1)</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Estrogen Receptor β:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> ERβ (Estrogen Receptor β or NR3A2 or ESR2) – This is also nuclear receptor and activated by the sex hormone estrogen which is located at chromosome number 14 (14q23.2). </span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">I ERβ has both N-terminal has DNA binding domain and C-terminal has ligand binding domain. This is localized to the nucleus, cytoplasm, and mitochondria. Selective estrogen receptor modulators (SERM) inhibits the ERβ. Drugs used as SERM are </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">clomiphene</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">, tamoxifen, raloxifene etc.</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Biological compartments:</span></span></strong> <span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Estrogen receptors (ER) are present in the plasma membrane. Both ERα and ERβ have diverse functions depending on cells and organs. ERs have also been loacated in cytoplasmic organelles including mitochondria and the endoplasmic reticulum</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Levin, 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">General role in biology:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> Estrogen receptors (both </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">) binds the estrogens to promote the t</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">he biological functions of estrogens. Depending upon a balance between ERα and ERβ activities in target organs, estrogen signaling is selectively stimulated or inhibited </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Welboren et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. ERβ has a high degree of sequence homology with the classical estrogen receptor. Interestingly, ERβ is detected in many tissues, including those previously assumed to be estrogen insensitive. In tissues where both ERs are expressed, such as the hypothalamus, uterus, mammary glands, and immune system, ERα promotes proliferation whereas ERβ has pro-apoptotic and pro-differentiating functions</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Morani et al., 2008)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. ERα is present mainly in ovary (thecal cells) where as ERβ is found mainly in ovary (granulosa cells)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Paterni et al., 2014)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. ERα and ERβ is identical approximately 97% in the DNA-binding domain and approximately 56% in the ligand-binding domain</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Dahlman-Wright et al., 2006)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></span></span></p>
<h4>How it is Measured or Detected</h4>
<p><em><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Radioreceptor assay/The estrogen receptor binding assay (using Rat Uterine Cytosol)</span></span></em><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">: This assay identifies chemicals that have the potential to interact with the estrogen receptor (ER) <em>in vitro</em>. Principle of this particular assay is based on the competitive protein-binding methods. A radiolabelled ligand and an unlabelled ligand are presented together to a specific receptor. The radioactivity measurement provides the quantitative estimation of the bound and unbound fraction of the ligand with the receptor. All cytosolic estrogen receptor subtypes that are expressed in the specific tissue, including ERα and ERβ are used for the determination of estrogen receptor binding. This assay is simple and rapid to perform when optimal conditions for binding are determined. Assay determines if a ligand/chemical can interact and displace the endogenous hormone 17β-estradiol </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Freyberger et al., 2010)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></p>
<h4>References</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Adashi, E. Y., Hsueh, A. J., & Yen, S. S. (1980). Alterations induced by clomiphene in the concentrations of oestrogen receptors in the uterus, pituitary gland and hypothalamus of female rats. <em>J Endocrinol. </em>, 87(3), 383-92.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Bharti, S., Misro, M., & Rai, U. (2013). Clomiphene citrate potentiates the adverse effects of estrogen on rat testis and down-regulates the expression of steroidogenic enzyme genes. <em>Fertility and sterility</em>, 99(1), 140-148. e5.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Bondesson, M., Hao, R., Lin, C.-Y., Williams, C., & Gustafsson, J.-Å. (2015). Estrogen receptor signaling during vertebrate development. <em>Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms</em>, 1849(2), 142-151.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Bussenot, I., Parinaud, J., Clamagirand, C., Vieitez, G., & Pontonnier, G. (1990). Effect of clomiphene cirate on oestrogen secretion by human granulosa cells in culture. <em>Human Reproduction</em>, 5(5), 533-536.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Dahlman-Wright, K., Cavailles, V., Fuqua, S. A., Jordan, V. C., Katzenellenbogen, J. A., Korach, K. S., et al. (2006). International union of pharmacology. LXIV. Estrogen receptors. <em>Pharmacological reviews</em>, 58(4), 773-781.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Dominguez, R., & Micevych, P. (2010). Estradiol rapidly regulates membrane estrogen receptor alpha levels in hypothalamic neurons. <em>J Neurosci</em>, 30(38), 12589-96. doi:30/38/12589 [pii]</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">10.1523/JNEUROSCI.1038-10.2010.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Eick, G. N., & Thornton, J. W. (2011). Evolution of steroid receptors from an estrogen-sensitive ancestral receptor. <em>Molecular and cellular endocrinology</em>, 334(1-2), 31-38.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Freyberger, A., Wilson, V., Weimer, M., Tan, S., Tran, H. S., & Ahr, H. J. (2010). Assessment of a robust model protocol with accelerated throughput for a human recombinant full length estrogen receptor-alpha binding assay: protocol optimization and intralaboratory assay performance as initial steps towards validation. <em>Reprod Toxicol</em>, 30(1), 50-9. doi:S0890-6238(10)00003-1 [pii]</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kerin, J. F., Liu, J. H., Phillipou, G., & Yen, S. S. (1985). Evidence for a hypothalamic site of action of clomiphene citrate in women. <em>J Clin Endocrinol Metab. </em>, 61(2), 65-68.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kettel, L. M., Roseff, S. J., Berga, S. L., Mortola, J. F., & Yen, S. S. (1993). Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. <em>Fertil Steril. </em>, 59(3), 532-38.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Koch, Y., Dikstein, S., Superstine, E., & Sulman, F. G. (1971). THE EFFECT OF PROMETHAZINE AND CLOMIPHENE ON GONADOTROPHIN SECRETION IN THE RAT. <em>Journal of Endocrinology</em>, 49(1), 13-17. doi:10.1677/joe.0.0490013.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kurosawa, T., Hiroi, H., Momoeda, M., Inoue, S., & Taketani, Y. (2010). Clomiphene citrate elicits estrogen agonistic/antagonistic effects differentially via estrogen receptors αand β. <em>Endocrine journal</em>, 57(6), 517-521.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Levin, E. R. (2009). Plasma membrane estrogen receptors. <em>Trends in Endocrinology & Metabolism</em>, 20(10), 477-482.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Morani, A., Warner, M., & Gustafsson, J. Å. (2008). Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues. <em>Journal of internal medicine</em>, 264(2), 128-142.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Oride, A., Kanasaki, H., Tumurbaatar, T., Zolzaya, T., Okada, H., Hara, T., et al. (2020). Effects of the Fertility Drugs Clomiphene Citrate and Letrozole on Kiss-1 Expression in Hypothalamic Kiss-1-Expressing Cell Models. <em>Reproductive sciences (Thousand Oaks, Calif.)</em>, 27. doi:10.1007/s43032-020-00154-1.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Paterni, I., Granchi, C., Katzenellenbogen, J. A., & Minutolo, F. (2014). Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential. <em>Steroids</em>, 90, 13-29.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Sutaria, U., Crooke, A., Bertrand, P., & Hodgson, C. (1980). Clomiphene citrate and human chorionic gonadotropin in the treatment of anovulatory infertility. <em>International Journal of Gynecology & Obstetrics</em>, 18(6), 435-437.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Taheripanah, R., Kabir-Salmani, M., Favayedi, M., Zamaniyan, M., Malih, N., & Taheripanah, A. (2020). Effects of clomiphene citrate plus estradiol or progesterone on endometrial ultrastructure: An RCT. <em>International Journal of Reproductive BioMedicine</em>, 18(3), 201.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Trost, L. W., & Khera, M. (2014). Alternative treatment modalities for the hypogonadal patient. <em>Current urology reports</em>, 15(7), 1-12.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Wahab, O. A., Princely, A. C., Oluwadamilare, A. A., Ore-Oluwapo, D. O., Blessing, A. O., & Alfred, E. F. (2019). Clomiphene citrate ameliorated lead acetate-induced reproductive toxicity in male Wistar rats. <em>JBRA assisted reproduction</em>, 23(4), 336-343. doi:10.5935/1518-0557.20190038.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Welboren, W.-J., Sweep, F. C., Span, P. N., & Stunnenberg, H. G. (2009). Genomic actions of estrogen receptor?: what are the targets and how are they regulated? <em>Endocrine-related cancer</em>, 16(4), 1073.</span></span></span></span></p>
<p style="text-align:justify"> </p>
<p style="text-align:justify"> </p>
<h3>List of Key Events in the AOP</h3>
<h4><a href="/events/1047">Event: 1047: Increased, secretion of GnRH from hypothalamus</a></h4>
<h5>Short Name: Increased, secretion of GnRH from hypothalamus</h5>
<td><a href="/aops/165">Aop:165 - Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse</a></td>
<td>KeyEvent</td>
</tr>
<tr>
<td><a href="/aops/440">Aop:440 - Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td>KeyEvent</td>
</tr>
<tr>
<td><a href="/aops/623">Aop:623 - Activation, estrogen receptor alpha leads to persistent vaginal cornification via increased kisspeptin release</a></td>
<em>Sex: Applies to both males and females as both sexes require GnRH signalling for regulation of various hormone pathways.</em></p>
<p><br />
<em>Taxonomic: Primarily studied in laboratory rodents and humans. Plausible for most mammals due to conserved hormone pathways regulating hypothalamus-pituitary-gonadal axis processes. GnRH widespread among vertebrates, including amphibians, reptiles, birds, and mammals (Duan and Allard 2020). </em><br />
</p>
<h4>Key Event Description</h4>
<p><em>Gonadotropin-releasing hormone (GnRH) is a key signalling hormone in the hypothalamus- pituitary-gonadal (HPG) axis in mammals produced by the hypothalamus. Gonadotropin-releasing hormone is a peptide hormone composed of 10 amino acids (Hassanein et al. 2024). The C terminal (Pro-Gly-NH2) is involved in receptor binding, with the N-terminal (pGlu-His-Trp-Ser) involved in receptor activation (Hassanein et al. 2024). Increased levels of GnRH occur due to increased secretion from the hypothalamus.</em></p>
<h4>How it is Measured or Detected</h4>
<p><em>GnRH can be measured via immunoassay or Western blotting (studies that utilized this approach include Clarkson et al. 2008; Kriszt et al. 2015; Bo et al. 2022), and include commercially available ELISA kits (e.g. Elabscience E-EL-0071 (universal; no cross-species reactivity); Assay Genie HUFI02509 (human); Cusabio CSB-E06880h (human); Biomatik EKC39138-96T (rat)). Mention of trade names or commercial products does not constitute endorsement or recommendation for use. </em></p>
<p><br />
<em>Real time PCR can be used to measure GnRH transcript abundance, which is an indirect – and only semi-quantitative indicator of GnRH hormone levels (studies that utilized this approach include Wang et al. 2014; Kriszt et al. 2015; Zhou et al. 2023). </em><br />
</p>
<h4>References</h4>
<p><em>Bo T, Liu M, Tang L, Lv J, Wen J, Wang D. 2022. Effects of High-Fat Diet During Childhood on Precocious Puberty and Gut Microbiota in Mice. Frontiers in Microbiology 13: 930747.</em></p>
<p><br />
<em>Clarkson J, d’Anglemont de Tassigny X, Moreno AS, Colledge WH, Herbison AE. 2008. Kisspeptin–GPR54 signaling is essential for preovulatory gonadotropin-releasing hormone neuron activation and the luteinizing hormone surge. Journal of Neuroscience 28(35): 8691–8697.</em></p>
<p><br />
<em>Duan C, Allard J. 2020. Gonadotropin-releasing hormone neuron development in vertebrates. General and Comparative Endocrinology. 292: 113465</em></p>
<p><br />
<em>Hassanein, E.M., Szelényi, Z., Szenci, O. 2024. Gonadotropin-Releasing Hormone (GnRH) and Its Agonists in Bovine Reproduction I: Structure, Biosynthesis, Physiological Effects, and Its Role in Estrous Synchronization. Animals 14: 1473.</em></p>
<p><br />
<em>Kriszt R, Winkler Z, Polyak A, Kuti D, Molnar C, Hrabovszky E, Kallo I, Szoke Z, Ferenczi S, Kovacs KJ. 2015. Xenoestrogens Ethinyl Estradiol and Zearalenone Cause Precocious Puberty in Female Rats via Central Kisspeptin Signaling. Endocrinology 156(11): 3996-4007.</em></p>
<p><br />
<em>Wang X, Chang F, Bai Y, Chen F, Zhang J, Chen L. 2014. Bisphenol A enhances kisspeptin neurons in anteroventral periventricular nucleus of female mice. Journal of Endocrinology 28(35): 201-213.</em></p>
<p><br />
<em>Zhou L, Ren Y, Li D, Zhou W, Li C, Wang Q, Yang X. 2023. Timosaponin AIII attenuates precocious puberty in mice through downregulating the hypothalamic-pituitary-gonadal axis. Acta Biochimica Polonica 70(1): 183-190.</em></p>
<p><br />
<em>NOTE: Italics indicate edits from John Frisch January 2026. A full list of updates can be found in the Change Log on the View History page.</em><br />
</p>
<h4><a href="/events/1050">Event: 1050: Increased, secretion of LH from anterior pituitary</a></h4>
<h5>Short Name: Increased, secretion of LH from anterior pituitary</h5>
<td><a href="/aops/165">Aop:165 - Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse</a></td>
<td>KeyEvent</td>
</tr>
<tr>
<td><a href="/aops/440">Aop:440 - Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td><a href="/aops/440">Aop:440 - Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Biological state: </span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Steroidogenic acute regulatory protein (StAR) plays important role in luteal steroidogenesis</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Christenson and Devoto, 2003)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Steroidogenic acute regulatory protein (StAR) controls the transport of cholesterol from the outer to inner mitochondrial membrane</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Stocco, 2000)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. There are several pathways involved for the transport of cholesterol from different subcellular pools into the inner mitochondria</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Martin et al., 2016)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Biological compartments:</span></span></strong> <span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Cholesterol is one type of lipid which is crystalline solid with yellow colour. It is <a href="https://en.wikipedia.org/wiki/Biosynthesis" title="Biosynthesis">biosynthesized</a> by animal <a href="https://en.wikipedia.org/wiki/Cell_(biology)#Eukaryotic_cells" title="Cell (biology)">cells</a> and is an essential structural component of <a href="https://en.wikipedia.org/wiki/Animal" title="Animal">animal</a> <a href="https://en.wikipedia.org/wiki/Cell_membrane" title="Cell membrane">cell membranes</a> </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Hanukoglu, 1992)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. It is the precursor molecule for the synthesis all <a href="https://en.wikipedia.org/wiki/Steroid_hormones" title="Steroid hormones">steroid hormones</a></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Payne and Hales, 2004)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Cytochrome P450 enzymes are present in most tissues of the body, and play important roles in <a href="https://en.wikipedia.org/wiki/Hormone" title="Hormone">hormone</a> synthesis in mitochondria using <a href="https://en.wikipedia.org/wiki/Cholesterol" title="Cholesterol">cholesterol</a> as precursor</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Poderoso et al., 2013)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">General role in biology:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> It is been reported that high in cholesterol levels in mitochondrial resulted several diseases like cancer, neurodegenerative diseases, steatohepatitis ischemia, and influence disease </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Martin et al., 2016)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. The alteration in mitochondrial cholesterol import may change the cholesterol concentrations that may lead to proper mitochondrial function along with biophysical properties of mitochondrial membranes. In absence of StAR protein, cholesterol transport into the mitochondria did not occurs leading to no conversion of progesterone from cholesterol precursors doesn’t occur</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Kiriakidou et al., 1996; Pescador et al., 1996)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. All Steroidogenic acute regulatory protein (StAR) promoters contain steroidogenic factor 1 binding sites which is responsible for sex hormones regulation</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Manna et al., 2002)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">One of the important function of the steroid hormones is maintaining reproductive capacity. For this purpose, steroidogenic cells must move large amounts of cholesterol from the outer mitochondrial membrane to the inner membrane. In the granulosa cells, this cholesterol is ultimately converted to progesterone. The initial transport of cholesterol across the mitochondrial membrane requires Steroidogenic Acute Regulatory (StAR) protein. Expression of StAR protein in preovulatory cells of the developing follicle is low. The dramatic upregulation of StAR protein expression within the dominant follicle is found after the luteinizing hormone (LH) surge. This upregulation allows the corpus luteum to produce substantial amounts of progesterone to maintain the reproductive capacity in human/animal </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Men et al., 2017; Stocco, 2000)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<h4>How it is Measured or Detected</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">StAR protein is measure by quantitative real time PCR (qRT-PCR): </span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">For qRT-PCR analyses, cDNA is synthesized using reagent kit in a 20-μl reaction containing 0.5 μg of total RNA collected from human ovarian granulosa tumor cell line ( KGN cells ), mouse Leydig cells. qPCR is performed in a 25-μl reaction containing 0.5 to 1.5 μl of cDNA using fluorescein in real-time PCR detection systems. PCR was performed by initial denaturation at 95°C for 5 minutes, followed by 40 cycles of 30 seconds at 95°C, 30 seconds at 60°C, and 30 seconds at 72°C. The threshold cycle values of each sample are used to calculate mRNA levels. The PCR primers for the indicated human and mouse genes are as follows </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Men et al., 2017)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Human StAR forward: 5′-GGCATCCTTAGCAACCAAGA</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Human StAR reverse: 5′-TCTCCTTGACATTGGGGTTC</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Mouse StAR forward: 5′-TTGGGCATACTCAACAACCA</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Mouse StAR reverse: 5′-GAAACACCTTGCCCACATCT</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Indirect immunohistochemistry for the detection of Steroidogenic Acute Regulatory Protein (StAR): </span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Ovarian or peritoneal tissues from the human patients are collected. Ovarian or peritoneal tissues from the patient are fixed using 10% paraformaldehyde. Tissues are embedded in paraffin. Serial sections of 5 µm are made using microtome. Tissue sections are prepared by microwave heating in 10× citrate buffer, pH 6.0, for 10 min. Tissues are rinsed three times in 20 mM phosphate buffered saline (PBS), pH 7.2, for 10 min each, before incubation with 1:200 dilutions of polyclonal anti-human StAR antibodies at 37°C for 60 min. Tissue sections were washed three times in 20 mM PBS, pH 7.2, for 2 min each, before incubation with a 1:1000 dilution of secondary mouse– anti-rabbit antibody at 37°C for 30 min. Indirect immunohistochemistry kits were used according to the manufacturer’s instructions to visualize StAR protein stained tissue under microscope and image collected. A pathological image analysis system is used to measure mean optical density (MOD) analysis under high-magnification (×400) microscopy. The MOD, which reflected the positive staining intensity, and the positive staining ratio (area %) of every positively stained area, are measured. The area % is calculated as ([the area of positive staining]/[total nuclear area in the field of view]) × 100. The MOD and area % are used to calculate the expression index, EI (%) = MOD × area %</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Tian et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<h4>References</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Baker, B. Y., Epand, R. F., Epand, R. M., & Miller, W. L. (2007). Cholesterol binding does not predict activity of the steroidogenic acute regulatory protein, StAR. <em>J Biol Chem</em>, 282(14), 10223-32. doi:S0021-9258(19)57693-1 [pii]</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Chaffin, C., Dissen, G., & Stouffer, R. (2000). Hormonal regulation of steroidogenic enzyme expression in granulosa cells during the peri-ovulatory interval in monkeys. <em>Molecular human reproduction</em>, 6(1), 11-18.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Christenson, L. K., & Devoto, L. (2003). Cholesterol transport and steroidogenesis by the corpus luteum. <em>Reproductive Biology and Endocrinology</em>, 1(1), 1-9.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Hanukoglu, I. (1992). Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis. <em>The Journal of steroid biochemistry and molecular biology</em>, 43(8), 779-804.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Hasegawa, T., Zhao, L., Caron, K. M., Majdic, G., Suzuki, T., Shizawa, S., et al. (2000). Developmental roles of the steroidogenic acute regulatory protein (StAR) as revealed by StAR knockout mice. <em>Mol Endocrinol</em>, 14(9), 1462-71. doi:10.1210/mend.14.9.0515.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kiriakidou, M., Mcallister, J. M., Sugawara, T., & Strauss 3rd, J. (1996). Expression of steroidogenic acute regulatory protein (StAR) in the human ovary. <em>The Journal of Clinical Endocrinology & Metabolism</em>, 81(11), 4122-4128.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Manna, P. R., Dyson, M. T., Eubank, D. W., Clark, B. J., Lalli, E., Sassone-Corsi, P., et al. (2002). Regulation of steroidogenesis and the steroidogenic acute regulatory protein by a member of the cAMP response-element binding protein family. <em>Molecular Endocrinology</em>, 16(1), 184-199.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Martin, L. A., Kennedy, B. E., & Karten, B. (2016). Mitochondrial cholesterol: mechanisms of import and effects on mitochondrial function. <em>Journal of bioenergetics and biomembranes</em>, 48(2), 137-151.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Men, Y., Fan, Y., Shen, Y., Lu, L., & Kallen, A. N. (2017). The Steroidogenic Acute Regulatory Protein (StAR) Is Regulated by the H19/let-7 Axis. <em>Endocrinology</em>, 158(2), 402-409. doi:10.1210/en.2016-1340.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Payne, A. H., & Hales, D. B. (2004). Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. <em>Endocrine reviews</em>, 25(6), 947-970.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Pescador, N., Soumano, K., Stocco, D. M., Price, C. A., & Murphy, B. D. (1996). Steroidogenic acute regulatory protein in bovine corpora lutea. <em>Biology of reproduction</em>, 55(2), 485-491.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Poderoso, C., Duarte, A., Cooke, M., Orlando, U., Gottifredi, V., Solano, A. R., et al. (2013). The spatial and temporal regulation of the hormonal signal. Role of mitochondria in the formation of a protein complex required for the activation of cholesterol transport and steroids synthesis. <em>Molecular and cellular endocrinology</em>, 371(1-2), 26-33.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Sreerangaraja Urs, D. B., Wu, W.-H., Komrskova, K., Postlerova, P., Lin, Y.-F., Tzeng, C.-R., et al. (2020). Mitochondrial function in modulating human granulosa cell steroidogenesis and female fertility. <em>International journal of molecular sciences</em>, 21(10), 3592.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Stocco, D. (2000). The role of the StAR protein in steroidogenesis: challenges for the future. <em>Journal of Endocrinology</em>, 164(3), 247-253.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Tian, Y., Kong, B., Zhu, W., Su, S., & Kan, Y. (2009). Expression of steroidogenic factor 1 (SF-1) and steroidogenic acute regulatory protein (StAR) in endometriosis is associated with endometriosis severity. <em>J Int Med Res</em>, 37(5), 1389-95. doi:10.1177/147323000903700513.</span></span></span></span></p>
<td><a href="/aops/440">Aop:440 - Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">It is applicable in reproduction system, cell growth and cell function</span></span></p>
<h4>Key Event Description</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Biological state:</span></span></strong><strong> </strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">The most </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">predominant form of estrogens is 17β-estradiol (E2) which is sex hormone. In women having premenopausal it is mainly produced in the ovaries. For postmenopausal women, it E2 primarily is sythesized from testosterone by aromatase enzyme in extragonadal tissues</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Simpson, 2003)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Estradiol stimulates both cell growth and cholesterogenesis in the MCF-7 line (breast cancer cell line) </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Cypriani et al., 1988)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Cholesterol increases neuronal estradiol release into the medium through synapse formation</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Fester et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Biological compartments:</span></span></strong><strong> </strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Estrogen is considered as the risk of developing cholesterol gallstones by enhancing the hepatic secretion of biliary cholesterol leading to an increase in cholesterol</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Wang et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">General role in biology:</span></span></strong> <span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">When estrogen levels decline, levels of low-density lipoprotein, the harmful kind of cholesterol increases, and levels of high-density lipoprotein, the positive kind of cholesterol decrease, due to which fat build up in the body and cholesterol in the arteries that causes heart attack and stroke</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Fåhraeus, 1988; Wahl et al., 1983)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Granulosa cells are the primary cell which provides the support and microenvironment required for the developing oocyte in the ovary</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Sen and Hammes, 2010; Sterneck et al., 1997)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<h4>How it is Measured or Detected</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Radioimmunoassay (RIA) and analytical method based on mass spectroscopic are used for estrogen measurement present in serum </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Smy and Straseski, 2018; Giese, 2003)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></span></span></p>
<h4>References</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Adashi, E., & Hsueh, A. (1982). Estrogens augment the stimulation of ovarian aromatase activity by follicle-stimulating hormone in cultured rat granulosa cells. <em>Journal of Biological Chemistry</em>, 257(11), 6077-6083.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Cypriani, B., Tabacik, C., & Descomps, B. (1988). Effect of estradiol and antiestrogens on cholesterol biosynthesis in hormone-dependent and-independent breast cancer cell lines. <em>Biochimica et Biophysica Acta (BBA)-Bioenergetics</em>, 972(2), 167-178.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Darabi, M., Rabbani, M., Ani, M., Zarean, E., Panjehpour, M., & Movahedian, A. (2011). Increased leukocyte ABCA1 gene expression in post-menopausal women on hormone replacement therapy. <em>Gynecological Endocrinology</em>, 27(9), 701-705.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Fåhraeus, L. (1988). The effects of estradiol on blood lipids and lipoproteins in postmenopausal women. <em>Obstetrics and gynecology</em>, 72(5 Suppl), 18S-22S.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Fester, L., Zhou, L., Bütow, A., Huber, C., Von Lossow, R., Prange‐Kiel, J., et al. (2009). Cholesterol‐promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus. <em>Hippocampus</em>, 19(8), 692-705.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Giese, R. W. (2003). Measurement of endogenous estrogens: analytical challenges and recent advances. <em>Journal of Chromatography A</em>, 1000(1), 401-412. doi:https://doi.org/10.1016/S0021-9673(03)00306-6.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Mao, Z., Li, J., & Zhang, W. (2018). Hormonal regulation of cholesterol homeostasis. <em>Cholesterol-Good, Bad and the Heart</em>.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Park, Y., Maizels, E. T., Feiger, Z. J., Alam, H., Peters, C. A., Woodruff, T. K., et al. (2005). Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad. <em>Journal of Biological Chemistry</em>, 280(10), 9135-9148.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Sen, A., & Hammes, S. R. (2010). Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. <em>Molecular endocrinology</em>, 24(7), 1393-1403.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Simpson, E. R. (2003). Sources of estrogen and their importance. <em>The Journal of steroid biochemistry and molecular biology</em>, 86(3-5), 225-230.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Smy, L., & Straseski, J. A. (2018). Measuring estrogens in women, men, and children: Recent advances 2012-2017. <em>Clin Biochem</em>, 62, 11-23.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Sterneck, E., Tessarollo, L., & Johnson, P. F. (1997). An essential role for C/EBPβ in female reproduction. <em>Genes & development</em>, 11(17), 2153-2162.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Wahl, P., Walden, C., Knopp, R., Hoover, J., Wallace, R., Heiss, G., et al. (1983). Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. <em>New England Journal of Medicine</em>, 308(15), 862-867.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Wang, H. H., Liu, M., Clegg, D. J., Portincasa, P., & Wang, D. Q.-H. (2009). New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation. <em>Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids</em>, 1791(11), 1037-1047.</span></span></span></span></p>
<td><a href="/aops/168">Aop:168 - GnRH pulse disruption leading to mammary adenomas and carcinomas in the SD rat.</a></td>
<td>KeyEvent</td>
</tr>
<tr>
<td><a href="/aops/169">Aop:169 - GnRH pulse disruption leading to pituitary adenomas and carcinomas in the SD rat.</a></td>
<td>KeyEvent</td>
</tr>
<tr>
<td><a href="/aops/440">Aop:440 - Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td>KeyEvent</td>
</tr>
<tr>
<td><a href="/aops/561">Aop:561 - Aromatase induction leading to estrogen receptor alpha activation via increased estradiol</a></td>
<td><a href="/aops/165">Aop:165 - Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse</a></td>
<td>KeyEvent</td>
</tr>
<tr>
<td><a href="/aops/440">Aop:440 - Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td><a href="/aops/165">Aop:165 - Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse</a></td>
<td>AdverseOutcome</td>
</tr>
<tr>
<td><a href="/aops/440">Aop:440 - Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td><a href="/aops/440">Aop:440 - Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">It is applicable in ovary for reproductive matured female.</span></span></span></span></p>
<h4>Key Event Description</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Biological state:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif"> Ovarian cancer is fatal gynecological malignancy and ranked as fifth most commonly diagnosed cancer among women. Generally, mortality rate is highest (~ 50 %) from this cancer as there is lack of proper diagnosis at early stage</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Siegel et al. 2019)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Ovarian cancers are broadly categorised into three types based on origin of cells namely epithelial, stromal and germ cell cancers </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Gilks and Prat 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Recent research efforts revealed that numbers of molecular level (genome, transcriptome and proteome level) perturbations are responsible for the development and progression of ovarian cancer </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Cheng and Zhan 2017)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. There is need to develop a molecular level biomarker for early detection, treatment and development of personalized medicine. Understanding of molecular level interactions in large and complex biological networks using systems biology approach will be key factors to identify the major regulatory motifs </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Zhang et al. 2018)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. This approach not only reduces the animal experiments substantially, but will able to quick detect of key perturbations</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Biological compartments: </span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Recent studies have suggested that FSH stimulates the proliferation and invasion of ovarian cancer cells, inhibits apoptosis and facilitates neovascularisation </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Tao et al. 2013)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Earlier studies also have established that the estrogen (ER) and progesterone (PR) receptors are important prognostic indicators of breast and endometrial cancers, and epithelial ovarian cancer. Despite acceptance regarding the influence of reproductive hormones on ovarian cancer risk and considerable advances in the understanding of epithelial ovarian carcinogenesis on a molecular level, complete understanding of the biologic processes underlying malignant transformation of ovarian surface epithelium is still lacking </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Gharwan et al. 2015)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">General role in biology:</span></span></strong> <span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Malfunctioning of sex hormones (e.g., estradiol, estrone and progesterone) may result ovarian cancer </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Fooladi et al. 2020, Meehan and Sadar 2003)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Exposure to endocrine-disrupting chemicals (EDCs) in the form of occupational usage of pesticides, fungicides, herbicides, plasticizers, cosmetics, etc. are the cause of ovarian cancer </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Samtani et al. 2018)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Clomiphene which is used as drug to treat infertility and it is reported that this chemical increases the risk of ovarian cancer </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(McLemore et al. 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Clomiphene (molecular initiating event, MIE) stimulates the releasing of gonadotropin-releasing hormone (GnRH) from hypothalamic. Also, it stimulates the secretion of the Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from pituitary </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Cassidenti et al. 1992, Mungenast and Thalhammer 2014, Tomao et al. 2014)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. These hormones regulate the synthesis of sex hormons (e.g., estrogen) level </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Shoemaker et al. 2010, Tomao et al. 2014)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. These sex hormones are primarily produced in the gonads through a series of enzyme-mediated reactions from cholesterol (precursor) and control through complex signalling pathway along hypothalamus – pituitary - gonadal (HPG) axis </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Perkins et al. 2019, Shoemaker et al. 2010)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. The series of complex signalling pathways in ovary include G-protein cycle, G-protein activation, adenylate cyclase (AC) activation, cyclic AMP (cAMP) activation, protein kinase A (PKA) activation, steroidogenic factor 1 (SF1) and StAR transcription. Ultimately, this signalling pathway activates the StAR protein which regulates the intake of cholesterol into the inner mitochondria where synthesis of sex hormones takes place. It may be noted that cholesterol is the precursor of the sex hormones synthesis. Again, releasing of LH is regulated by estradiol and testosterone level resulting complex signalling pathway that includes genes, transcritome, proteome and metabolites </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Perkins et al. 2019, Shoemaker et al. 2010)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Under clomiphene exposure, synthesis of estrogen level becomes high resulting risk of ovarian cancer </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(McLemore et al. 2009, Tomao et al. 2014)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Therefore, perturbations of GnRH, FSH and LH can result adverse phenotype as ovarian cancer.</span></span></span></span></p>
<h4>How it is Measured or Detected</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Gossmann et al., had shown the effects of angiogenesis inhibition on tumor microvascular permeability was monitored with the help of magnetic resonance imaging (MRI) technique in a rat model of human ovarian cancer </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Gossmann et al. 2000)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. </span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Gitsch et al., had developed gamma-ray detection probe for overcoming the conventional radio-immunoscintigraphy problems for the detection of ovarian cancer in female patients </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Gitsch and Pateisky 1989)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. </span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Kim et al., had used the detection of magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) for the detection of ovarian tumor in human patient. Sensitivity and accuracy of the PET/CT technique for detecting the ovarian tumor was reported 73% and 91%. Whereas, the sensitivity and accuracy of the MRI technique was reported 81% and 89% </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Kim et al. 2007)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Harrington et al., had used immunotechniques (Anti-CDCP1 immuno-conjugates) for detection of the ovarian cancer. Expression and binding properties of the cell surface protein was detected in ovarian cancer cell (in vitro) using flow cytometry and western blot technique </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Harrington et al.)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">.</span></span></span></span></p>
<h4>Regulatory Significance of the AO</h4>
<p>Informations related with ovarian cancer will be helpful for the regulatory authorities to develop monographs, frame the rules of assesments and monitoring of the process.</p>
<h4>References</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Cassidenti, D.L., Paulson, R.J., Lobo, R.A. and Sauer, M.V. (1992) The synergistic effects of clomiphene citrate and human menopausal gonadotrophin in the folliculogenesis of stimulated cycles as assessed by the gonadotrophin-releasing hormone antagonist Nal-Glu. Hum Reprod 7(3), 344-348.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Cheng, T. and Zhan, X. (2017) Pattern recognition for predictive, preventive, and personalized medicine in cancer. EPMA J 8(1), 51-60.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Fooladi, S., Akbari, H., Abolhassani, M., Sadeghi, E. and Fallah, H. (2020) Estradiol, des-acylated, and total ghrelin levels might be associated with epithelial ovarian cancer in postmenopausal women. medRxiv.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Gharwan, H., Bunch, K.P. and Annunziata, C.M. (2015) The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocr Relat Cancer 22(6), R339-363.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Gilks, C.B. and Prat, J. (2009) Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 40(9), 1213-1223.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Gitsch, E. and Pateisky, N. (1989) Radio-immunoscintigraphy and intraoperative tumour detection by means of anti-tumour antibodies in patients with ovarian cancer. Baillieres Clin Obstet Gynaecol 3(1), 31-36.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Gossmann, A., Helbich, T.H., Mesiano, S., Shames, D.M., Wendland, M.F., Roberts, T.P., Ferrara, N., Jaffe, R.B. and Brasch, R.C. (2000) Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 183(4), 956-963.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Hollis, R.L.J.C.L. (2023) Molecular characteristics and clinical behaviour of epithelial ovarian cancers. 216057.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Jokerst, J.V., Cole, A.J., Van de Sompel, D. and Gambhir, S.S. (2012) Gold nanorods for ovarian cancer detection with photoacoustic imaging and resection guidance via Raman imaging in living mice. ACS Nano 6(11), 10366-10377.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Kim, C.K., Park, B.K., Choi, J.Y., Kim, B.G. and Han, H. (2007) Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J Comput Assist Tomogr 31(6), 868-875.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Liu, Y., Lin, X., Bao, T., Ni, P., Xie, C., Shen, H., Xu, W., Xu, H. and Su, Z. (2015) [Detection and correlation analysis of miRNAs and myeloid-derived suppressor cells in ovarian cancer-bearing mice]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 31(4), 467-469, 473.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">McLemore, M.R., Miaskowski, C., Aouizerat, B.E., Chen, L.M. and Dodd, M.J. (2009) Epidemiological and genetic factors associated with ovarian cancer. Cancer Nurs 32(4), 281-288; quiz 289-290.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Meehan, K.L. and Sadar, M.D. (2003) Androgens and androgen receptor in prostate and ovarian malignancies. Front Biosci 8, d780-800.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Mortlock, S., Corona, R.I., Kho, P.F., Pharoah, P., Seo, J.-H., Freedman, M.L., Gayther, S.A., Siedhoff, M.T., Rogers, P.A. and Leuchter, R.J.C.R.M. (2022) A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes. 3(3), 100542.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Mungenast, F. and Thalhammer, T. (2014) Estrogen biosynthesis and action in ovarian cancer. Front Endocrinol (Lausanne) 5, 192.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Perkins, E.J., Gayen, K., Shoemaker, J.E., Antczak, P., Burgoon, L., Falciani, F., Gutsell, S., Hodges, G., Kienzler, A., Knapen, D., McBride, M., Willett, C., Doyle, F.J. and Garcia-Reyero, N. (2019) Chemical hazard prediction and hypothesis testing using quantitative adverse outcome pathways. ALTEX 36(1), 91-102.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Samtani, R., Sharma, N. and Garg, D. (2018) Effects of Endocrine-Disrupting Chemicals and Epigenetic Modifications in Ovarian Cancer: A Review. Reprod Sci 25(1), 7-18.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Schneider, J., Jimenez, E., Marenbach, K., Romero, H., Marx, D. and Meden, H. (1999) Immunohistochemical detection of HSP60-expression in human ovarian cancer. Correlation with survival in a series of 247 patients. Anticancer Res 19(3A), 2141-2146.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Shoemaker, J.E., Gayen, K., Garcia-Reyero, N., Perkins, E.J., Villeneuve, D.L., Liu, L. and Doyle, F.J. (2010) Fathead minnow steroidogenesis: in silico analyses reveals tradeoffs between nominal target efficacy and robustness to cross-talk. BMC Systems Biology 4(1), 89.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1), 7-34.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Tao, X., Zhao, N., Jin, H., Zhang, Z., Liu, Y., Wu, J., Bast, R.C., Jr., Yu, Y. and Feng, Y. (2013) FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. Endocr Relat Cancer 20(3), 415-429.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Tomao, F., Lo Russo, G., Spinelli, G.P., Stati, V., Prete, A.A., Prinzi, N., Sinjari, M., Vici, P., Papa, A., Chiotti, M.S., Benedetti Panici, P. and Tomao, S. (2014) Fertility drugs, reproductive strategies and ovarian cancer risk. J Ovarian Res 7, 51.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Zhang, T., Xu, J., Deng, S., Zhou, F., Li, J., Zhang, L., Li, L., Wang, Q.-E. and Li, F. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLOS ONE 13(5), e0196351.</span></span></span></span></p>
<h2>Appendix 2</h2>
<h2>List of Key Event Relationships in the AOP</h2>
<div id="evidence_supporting_links">
<h3>List of Adjacent Key Event Relationships</h3>
<div>
<h4><a href="/relationships/2580">Relationship: 2580: Suppression, Estrogen receptor (ER) activity leads to Increased, secretion of GnRH from hypothalamus</a></h4>
<td><a href="/aops/440">Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td>adjacent</td>
<td>High</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>
</div>
<h4>Evidence Supporting Applicability of this Relationship</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Negative feedback action on GnRH secretion had shown in female guinea pig </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Kelly et al., 1984)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Reduced firing of GnRH neurone was shown in adult female mice </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Chu et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Alterations in the concentrations of oestrogen receptors in the hypothalamus was shown in rat </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Adashi et al., 1980)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Negative Feedback of estrogen on GnRH secretion was studied in adult woman </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Shaw et al., 2010)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<h4>Key Event Relationship Description</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Study on female human patient had shown Selective Estrogen Receptors Modulator (Clomiphene) act on the hypothalamic site and increase the hypothalamic GnRH secretion significantly </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(KERIN et al., 1985)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Study on female rat had shown increased gonadotropin hormone secretion upon administration of very low dose (1-100 ng/kg) of clomiphene citrate. However, high dose (1µg/kg -2 mg/kg) of clomiphene citrate in female rat inhibit the gonadotropin hormone secretion </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Koch et al., 1971)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Estradiol i.e. Estrogen receptor beta acts as a potent feedback molecule between the ovary and hypothalamic GnRH neurons, and exerts both positive and negative regulatory actions on GnRH synthesis and secretion </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Hu et al., 2008)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. ESR<sub>2 </sub>control the GnRH release through the intracellular calcium ions release </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Kenealy et al., 2011)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Research had shown that nanomolar concentration of membrane-associated G protein-coupled estrogen receptor alter the patterns of Ca2+ release in GnRH neurone </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Komatsuzaki and Kawato, 2007)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Studies on mouse have shown several molecules such as, eastradiol, non-peptide neurotransmitters, gasotransmitters can modulate the GnRH neuron activity and GnRH secretion and control the reproductive functions </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Spergel, 2019; Temple et al., 2004; Temple and Wray, 2005)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<h4>Evidence Supporting this KER</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Koch et al., had shown the ~107% increase in GnRH secretion after administration of clomiphene citrate (1-100 ng/kg) in adult female rat </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Koch et al., 1971)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Boyer et al., had also shown the increasing GnRH secretion after administration of clomiphene citrate (1.0 mg/kg/day)in immature female rats </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Boyar, 1970)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Roy et al., had shown that 17β-estradiol at 1 nm concentration over a 48 h time period down regulate (~55%) the expression of GnRH mRNA in GnRH-secreting, hypothalamic cell line (GT1–7) </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Roy et al., 1999)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Chu et al., had shown using whole cell electrophysiology of the brain slice in adult female mice 10 picomolar concentration of estradiol reduce the firing of GnRH neurone </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Chu et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<strong>Biological Plausibility</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Molecular mechanism for the enhancement of GnRH by suppression of Estrogen receptor activity is poorly known.</span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">~55% down regulation of the expression of GnRH mRNA.</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Roy et al., 1999)</span></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<strong>Uncertainties and Inconsistencies</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">The release GnRH neurons depends on the concentration of the Selective Estrogen Receptors Modulator compound (Clomiphene). Scientific reports have shown the both stimulatory and inhibitory effects on the GnRH secretion exhibited by the estradiol depending on the concentration of clomiphene molecules and presence of types of receptors </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Chu et al., 2009; Micevych and Kelly, 2012; Boyar, 1970)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></p>
<h4>Quantitative Understanding of the Linkage</h4>
<p>Not Specified</p>
<strong>Response-response relationship</strong>
<p>Not Specified</p>
<strong>Time-scale</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Neural activity and elevated hormone release are observed for hours in in vivo study </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Chu et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<strong>Known modulating factors</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">GnRH secretion from the neurone can be modulated by prostaglandin, glutamate, ATP, carbon monoxide, nitric oxide, neurotransmitters (norepinephrine, epinephrine, GABA, histamine and acetylcholine) </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Spergel, 2019)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<strong>Known Feedforward/Feedback loops influencing this KER</strong>
<p>Not Specified</p>
<h4>References</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Adashi, E., Hsueh, A., & Yen, S. (1980). Alterations induced by clomiphene in the concentrations of oestrogen receptors in the uterus, pituitary gland and hypothalamus of female rats. <em>Journal of Endocrinology</em>, 87(3), 383-392.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Baez-Jurado, E., Rincon-Benavides, M. A., Hidalgo-Lanussa, O., Guio-Vega, G., Ashraf, G. M., Sahebkar, A., et al. (2018). Molecular mechanisms involved in the protective actions of Selective Estrogen Receptor Modulators in brain cells. <em>Front Neuroendocrinol</em>, 52, 44-64. doi:S0091-3022(18)30094-3 [pii]10.1016/j.yfrne.2018.09.001.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Bharti, S., Misro, M., & Rai, U. (2013). Clomiphene citrate potentiates the adverse effects of estrogen on rat testis and down-regulates the expression of steroidogenic enzyme genes. <em>Fertility and sterility</em>, 99(1), 140-148. e5.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Boyar, R. M. (1970). Effects of clomiphene citrate on pituitary FSH, FSH-RF, and release of LH in immature and mature rats. <em>Endocrinology</em>, 86(3), 629-33. doi:10.1210/endo-86-3-629.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Bussenot, I., Parinaud, J., Clamagirand, C., Vieitez, G., & Pontonnier, G. (1990). Effect of clomiphene cirate on oestrogen secretion by human granulosa cells in culture. <em>Human Reproduction</em>, 5(5), 533-536.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Chu, Z., Andrade, J., Shupnik, M. A., & Moenter, S. M. (2009). Differential regulation of gonadotropin-releasing hormone neuron activity and membrane properties by acutely applied estradiol: dependence on dose and estrogen receptor subtype. <em>J Neurosci</em>, 29(17), 5616-27. doi:29/17/5616 [pii]10.1523/JNEUROSCI.0352-09.2009.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Couse, J. F., & Korach, K. S. (1999). Estrogen receptor null mice: what have we learned and where will they lead us? <em>Endocr Rev</em>, 20(3), 358-417. doi:10.1210/edrv.20.3.0370.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Goerzen, J., Corenblum, B., & Taylor, P. J. (1985). Potentiation of GnRH response by clomiphene citrate. <em>J Reprod Med</em>, 30(10), 749-52.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Haskell, S. G. (2003). Selective estrogen receptor modulators. <em>South Med J</em>, 96(5), 469-76. doi:10.1097/01.SMJ.0000051146.93190.4A.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Hu, L., Gustofson, R. L., Feng, H., Ki Leung, P., Mores, N., Krsmanovic, L. Z., et al. (2008). Converse regulatory functions of estrogen receptor-α and-β subtypes expressed in hypothalamic gonadotropin-releasing hormone neurons. <em>Molecular Endocrinology</em>, 22(10), 2250-2259.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kelly, M. J., Ronnekleiv, O. K., & Eskay, R. L. (1984). Identification of estrogen-responsive LHRH neurons in the guinea pig hypothalamus. <em>Brain Res Bull</em>, 12(4), 399-407. doi:0361-9230(84)90112-6 [pii]10.1016/0361-9230(84)90112-6.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kenealy, B., Keen, K., & Terasawa, E. (2011). Rapid action of estradiol in primate GnRH neurons: the role of estrogen receptor alpha and estrogen receptor beta. <em>Steroids</em>, 76(9), 861-866.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">KERIN, J. F., LIU, J. H., PHILLIPOU, G., & Yen, S. (1985). Evidence for a hypothalamic site of action of clomiphene citrate in women. <em>The Journal of Clinical Endocrinology & Metabolism</em>, 61(2), 265-268.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Koch, Y., Dikstein, S., Superstine, E., & Sulman, F. G. (1971). The effect of promethazine and clomiphene on gonadotrophin secretion in the rat. <em>J Endocrinol</em>, 49(1), 13-7. doi:10.1677/joe.0.0490013.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Komatsuzaki, Y., & Kawato, S. (2007). Rapid Effect of Progesterone on the Intracellular Ca2+ Oscillation of Immortalized Hypothalamic GT1-7 Cells. <em>bioimages</em>, 15, 1-7.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kumar, A., & Pakrasi, P. L. (1995). Estrogenic and antiestrogenic properties of clomiphene citrate in laboratory mice. <em>Journal of Biosciences</em>, 20(5), 665-673.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Micevych, P. E., & Kelly, M. J. (2012). Membrane estrogen receptor regulation of hypothalamic function. <em>Neuroendocrinology</em>, 96(2), 103-10. doi:000338400 [pii]10.1159/000338400.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Ng, Y., Wolfe, A., Novaira, H. J., & Radovick, S. (2009). Estrogen regulation of gene expression in GnRH neurons. <em>Molecular and cellular endocrinology</em>, 303(1-2), 25-33.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Petersen, S. L., McCrone, S., Keller, M., & Shores, S. (1995). Effects of estrogen and progesterone on luteinizing hormone-releasing hormone messenger ribonucleic acid levels: consideration of temporal and neuroanatomical variables. <em>Endocrinology</em>, 136(8), 3604-10. doi:10.1210/endo.136.8.7628399.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Roy, D., Angelini, N. L., & Belsham, D. D. (1999). Estrogen directly represses gonadotropin-releasing hormone (GnRH) gene expression in estrogen receptor-α (ERα)-and ERβ-expressing GT1–7 GnRH neurons. <em>Endocrinology</em>, 140(11), 5045-5053.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Shaw, N. D., Histed, S. N., Srouji, S. S., Yang, J., Lee, H., & Hall, J. E. (2010). Estrogen negative feedback on gonadotropin secretion: evidence for a direct pituitary effect in women. <em>J Clin Endocrinol Metab</em>, 95(4), 1955-61. doi:jc.2009-2108 [pii]10.1210/jc.2009-2108.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Spergel, D. J. (2019). Modulation of Gonadotropin-Releasing Hormone Neuron Activity and Secretion in Mice by Non-peptide Neurotransmitters, Gasotransmitters, and Gliotransmitters. <em>Front Endocrinol (Lausanne)</em>, 10, 329. doi:10.3389/fendo.2019.00329.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Tan, S. L., Farhi, J., Homburg, R., & Jacobs, H. S. (1996). Induction of ovulation in clomiphene-resistant polycystic ovary syndrome with pulsatile GnRH. <em>Obstet Gynecol</em>, 88(2), 221-6. doi:0029-7844(96)00190-1 [pii]10.1016/0029-7844(96)00190-1.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Temple, J. L., Laing, E., Sunder, A., & Wray, S. (2004). Direct action of estradiol on gonadotropin-releasing hormone-1 neuronal activity via a transcription-dependent mechanism. <em>J Neurosci</em>, 24(28), 6326-33. doi:10.1523/JNEUROSCI.1006-04.200424/28/6326 [pii].</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Temple, J. L., & Wray, S. (2005). Bovine serum albumin-estrogen compounds differentially alter gonadotropin-releasing hormone-1 neuronal activity. <em>Endocrinology</em>, 146(2), 558-63. doi:en.2004-1117 [pii]10.1210/en.2004-1117.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Zhang, Z., Bartsch, J. W., Benzel, J., Lei, T., Nimsky, C., & Voellger, B. (2009). Selective estrogen receptor modulators decrease invasiveness in pituitary adenoma cell lines AtT-20 and TtT/GF by affecting expression of MMP-14 and ADAM12. <em>FEBS Open Bio</em>, 10(11), 2489-2498. doi:10.1002/2211-5463.12999.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Zoeller, R. T., & Young, W. S., 3rd (1988). Changes in cellular levels of messenger ribonucleic acid encoding gonadotropin-releasing hormone in the anterior hypothalamus of female rats during the estrous cycle. <em>Endocrinology</em>, 123(3), 1688-9. doi:10.1210/endo-123-3-1688.</span></span></span></span></p>
</div>
<div>
<h4><a href="/relationships/1089">Relationship: 1089: Increased, secretion of GnRH from hypothalamus leads to Increased, secretion of LH from anterior pituitary</a></h4>
<td><a href="/aops/165">Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse</a></td>
<td>adjacent</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td><a href="/aops/440">Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td>adjacent</td>
<td>High</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
</div>
<h4>Evidence Supporting Applicability of this Relationship</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">The release of gonadotrophin-releasing hormone (GnRH) stimulate the secretion of luteinising hormone (LH) </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Fields et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. GnRH causes the pituitary gland to secrete LH. Gonadotropin releasing hormone (GnRH) is the key regulator of the secretion of luteinising hormone </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Marques et al., 2018; Bowen et al., 1998; Tsutsumi and Webster, 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Metastin or kisspeptin in the control of gonadotropin-releasing hormone (GnRH) release and then it causes for pulsatile release of luteinizing hormone</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Ohkura et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></span></span></p>
<h4>Evidence Supporting this KER</h4>
<ul>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Gonadotropin-releasing hormone (GnRH) is the master hormone for regulating the reproduction. GnRH pulses stimulate the synthesis and secretion of LH from the anterior pituitary</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Tsutsumi and Webster, 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></li>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Nicol et al., reported that high GnRH dose enhances the secretion of LH </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Nicol et al., 2002)</span></span></span></span></li>
</ul>
<strong>Biological Plausibility</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">GnRH was isolated from porcine hypothalamus. It was structurally identified as a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly·NH2)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(AV et al., 971)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. During the childhood, GnRH levels are low but as </span></span><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">puberty </span></span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">begins. GnRH levels start to rise and when the </span></span><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">testes </span></span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">and </span></span><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">ovaries </span></span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">are fully developed. GnRH regulates LH and these hormones to control the production of sex hormones in adult </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Marques et al., 2018)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. GnRH secretion have been described in pulsatile (in minutes) and surge modes. Pulsatile mode refers to episodic release of GnRH while the surge mode of GnRH secretion occurs in females during the pre-ovulatory phase </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Maeda et al., 2010)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Secretion of LH is also in pulsatile nature ( in hrs)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Bolt, 1971)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Sonntag et al., 2005)</span></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<strong>Uncertainties and Inconsistencies</strong>
<p>Not Specified</p>
<h4>Quantitative Understanding of the Linkage</h4>
<ul>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Fields et al., studied the dose response of GnRH (100 micro gram) on cows and observed greater release of LH (25 %) aftrer 12-18 hours </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Fields et al., 2009)</span></span></span></span></li>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Crawford et al., used PCR techniques to study the effect of GnRH on LH in vivo on Possums. They reported the increase of LH quantitavely in absence of pulse of LH</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Crawford et al., 2009)</span></span></span></span></li>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Guillaume et al., studied the two GnRH antagonist Antarelix and Cetrorelix (0.01 mg/kg) on mare and observed that there is strong suppression of LH </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Guillaume et al., 2002)</span></span></span></span></li>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Washington et al., developed one mathematical model for the respose of LH under the pulsatile and continuous exposure of GnRH </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Washington et al., 2004</span></span></span></span></li>
<li><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Shoemaker</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> et al., developed a mathematical model on steroidogenesis in the fathead minnow. They quantified the relationship between GnRH and LH</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Shoemaker et al., 2010)</span></span></li>
</ul>
<strong>Response-response relationship</strong>
<p>Not Specified</p>
<strong>Time-scale</strong>
<ul>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Generally time scale is in hours (6-18) between GnRH and LH response </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Fields et al., 2009)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></span></span></li>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">GnRH is degraded by proteolysis within a few minutes</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Kenealy et al., 2011)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></span></span></li>
<li><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">It has very low activity during </span></span><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">childhood</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">, and is activated at </span></span><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">puberty</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> or </span></span><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">adolescence</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""> and in reproductive years, pulse activity is critical for successful reproductive function</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Berger et al., 1983)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. </span></span></li>
</ul>
<strong>Known modulating factors</strong>
<ul>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Protein kinase C cross-talk with gonadotrope progesterone receptor is involved in GnRH-induced LH secretion </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Garrido-Gracia et al., 2006)</span></span></span></span></li>
</ul>
<strong>Known Feedforward/Feedback loops influencing this KER</strong>
<p>Not Specified</p>
<h4>References</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Adashi, E., Hsueh, A., & Yen, S. (1980). Alterations induced by clomiphene in the concentrations of oestrogen receptors in the uterus, pituitary gland and hypothalamus of female rats. <em>Journal of Endocrinology</em>, 87(3), 383-392.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">AV, S., A, A., AJ, K., H, M., Y, B., TW, R., et al. (971). Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing. <em>Science</em>, 173(4001), 1036-38. doi:doi: 10.1126/science.173.4001.1036.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Berger, H., Nikolics, K., Szöke, B., & Mehlis, B. (1983). Proteolytic degradation of gonadotropin-releasing hormone (GnRH) by rat ovarian fractions in vitro. <em>Peptides</em>, 4(6), 821-825.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Bharti, S., Misro, M., & Rai, U. (2013). Clomiphene citrate potentiates the adverse effects of estrogen on rat testis and down-regulates the expression of steroidogenic enzyme genes. <em>Fertility and sterility</em>, 99(1), 140-148. e5.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Bolt, D. J. (1971). Changes in the concentration of luteinizing hormone in plasma of rams following administration of oestradiol, progesterone or testosterone. <em>J Reprod Fertil. </em>, 24(3), 435-38.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Botte, M., Lerrant, Y., Lozach, A., Berault, A., Counis, R., & Kottler, M. (1999). LH down-regulates gonadotropin-releasing hormone (GnRH) receptor, but not GnRH, mRNA levels in the rat testis. <em>Journal of Endocrinology</em>, 162(3), 409-415.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Bowen, J. M., Dahl, G. E., Evans, N. P., Thrun, L. A., Wang, Y., Brown, M. B., et al. (1998). Importance of the gonadotropin-releasing hormone (GnRH) surge for induction of the preovulatory luteinizing hormone surge of the ewe: dose-response relationship and excess of GnRH. <em>Endocrinology</em>, 139(2), 588-595.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Bussenot, I., Parinaud, J., Clamagirand, C., Vieitez, G., & Pontonnier, G. (1990). Effect of clomiphene cirate on oestrogen secretion by human granulosa cells in culture. <em>Human Reproduction</em>, 5(5), 533-536.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Concannon, P. W., Temple, M., Montanez, A., & Newton, L. (2006). Effects of dose and duration of continuous GnRH-agonist treatment on induction of estrus in beagle dogs: competing and concurrent up-regulation and down-regulation of LH release. <em>Theriogenology</em>, 66(6-7), 1488-96. doi:S0093-691X(06)00095-1 [pii]</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Crawford, J. L., Heath, D. A., Haydon, L. J., Thomson, B. P., & Eckery, D. C. (2009). Gene expression and secretion of LH and FSH in relation to gene expression of GnRH receptors in the brushtail possum (Trichosurus vulpecula) demonstrates highly conserved mechanisms. <em>Reproduction</em>, 137(1), 129-40. doi:REP-08-0347 [pii]</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">10.1530/REP-08-0347.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Fields, S. D., Perry, B. L., & Perry, G. A. (2009). Effects of GnRH treatment on initiation of pulses of LH, LH release, and subsequent concentrations of progesterone. <em>Domest Anim Endocrinol</em>, 37(4), 189-95. doi:S0739-7240(09)00038-1 [pii]</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">10.1016/j.domaniend.2009.04.006.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Garrido-Gracia, J. C., Bellido, C., Aguilar, R., & Sanchez-Criado, J. E. (2006). Protein kinase C cross-talk with gonadotrope progesterone receptor is involved in GnRH-induced LH secretion. <em>J Physiol Biochem</em>, 62(1), 35-42. doi:10.1007/BF03165804.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Guillaume, D., Bruneau, B., & Briant, C. (2002). Comparison of the effects of two GnRH antagonists on LH and FSH secretion, follicular growth and ovulation in the mare. <em>Reprod Nutr Dev</em>, 42(3), 251-64. doi:10.1051/rnd:2002023.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kenealy, B., Keen, K., & Terasawa, E. (2011). Rapid action of estradiol in primate GnRH neurons: the role of estrogen receptor alpha and estrogen receptor beta. <em>Steroids</em>, 76(9), 861-866.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">KERIN, J. F., LIU, J. H., PHILLIPOU, G., & Yen, S. (1985). Evidence for a hypothalamic site of action of clomiphene citrate in women. <em>The Journal of Clinical Endocrinology & Metabolism</em>, 61(2), 265-268.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kumar, A., & Pakrasi, P. L. (1995). Estrogenic and antiestrogenic properties of clomiphene citrate in laboratory mice. <em>Journal of Biosciences</em>, 20(5), 665-673.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Maeda, K., Ohkura, S., Uenoyama, Y., Wakabayashi, Y., Oka, Y., Tsukamura, H., et al. (2010). Neurobiological mechanisms underlying GnRH pulse generation by the hypothalamus. <em>Brain Res. </em>, 10, 103-115.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Marques, P., Skorupskaite, K., George, J. T., & Anderson, R. A. (2018). Physiology of GNRH and gonadotropin secretion. <em>Endotext [Internet]</em>.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Nicol, L., McNeilly, J. R., Stridsberg, M., Crawford, J. L., & McNeilly, A. S. (2002). Influence of steroids and GnRH on biosynthesis and secretion of secretogranin II and chromogranin A in relation to LH release in LbetaT2 gonadotroph cells. <em>J Endocrinol</em>, 174(3), 473-83. doi:JOE04823 [pii]</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">10.1677/joe.0.1740473.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Ohkura, S., Uenoyama, Y., Yamada, S., Homma, T., Takase, K., Inoue, N., et al. (2009). Physiological role of metastin/kisspeptin in regulating gonadotropin-releasing hormone (GnRH) secretion in female rats. <em>Peptides</em>, 30(1), 49-56.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Shoemaker, J. E., Gayen, K., Garcia-Reyero, Natà l., Perkins, E. J., Villeneuve, D. L., Liu, L., et al. (2010). Fathead minnow steroidogenesis: in silico analyses reveals tradeoffs between nominal target efficacy and robustness to cross-talk. <em>BMC Systems Biology</em>, 4(1), 89. doi:10.1186/1752-0509-4-89.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Sonntag, B., Kiesel, L., Nieschlag, E., & Behre, H. M. (2005). Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART. <em>J Assist Reprod Genet</em>, 22(7-8), 277-83. doi:10.1007/s10815-005-5998-8.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Tsutsumi, R., & Webster, N. J. (2009). GnRH pulsatility, the pituitary response and reproductive dysfunction. <em>Endocrine journal</em>, 56(6), 729-737.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Washington, T. M., Blum, J. J., Reed, M. C., & Conn, P. M. (2004). A mathematical model for LH release in response to continuous and pulsatile exposure of gonadotrophs to GnRH. <em>Theor Biol Med Model</em>, 1, 9. doi:10.1186/1742-4682-1-9</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">1742-4682-1-9 [pii].</span></span></span></span></p>
</div>
<div>
<h4><a href="/relationships/2581">Relationship: 2581: Increased, secretion of LH from anterior pituitary leads to Increased, Steroidogenic acute regulatory protein (StAR) </a></h4>
<td><a href="/aops/440">Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td>adjacent</td>
<td>High</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
</div>
<h4>Evidence Supporting Applicability of this Relationship</h4>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">The activity of StAR protein in theca cells is control by LH </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Murayama et al., 2012)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Subsequently, StAR protein regulates cholesterol transportation to the mitochondria and therefore, the production of steroid hormones is regulated by StAR protein </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Clark and Stocco, 1995)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<h4>Evidence Supporting this KER</h4>
<ul>
<li style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Murayama et al. studied the in vitro LH pulse dose in Bovine ovaries and reported LH dose enhances the activity of StAR protein </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Murayama et al., 2012)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></li>
<li style="text-align:justify"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Johnson and Bridgham performed in vitro studied in granulosa cells from prehierarchal and preovulatory hen follicles to examine the regulation of steroidogenic acute regulatory protein (StAR) by LH. They reported the treatment with LH rapidly increased StAR mRNA and protein </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Johnson and Bridgham, 2001)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></li>
</ul>
<strong>Biological Plausibility</strong>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">In mammalian species (e.g., rat,rabbit, human), LH stimulates the StAR protein to increase the cholesterol transport in to the inner mitochondrial membrane. Cholesterol is the precursor of sex hormones. Therefore, LH regulate the steroidogenic function of theca cells </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Murayama et al., 2012; Johnson and Bridgham, 2001; Rekawiecki et al., 2005)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">LH increases StAR protein activity</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">LH increases StAR protein activity</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">LH-induced StAR protein expression</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">LH increases StAR protein expression</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">LH increases StAR protein expression</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">LH increases five fold StAR protein expression</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Eacker et al., 2008)</span></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<strong>Uncertainties and Inconsistencies</strong>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">No uncertainties and inconsistencies are observed </span></span></span></span></p>
<h4>Quantitative Understanding of the Linkage</h4>
<ul>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Rekawieck et al. conducted the in vitro study on Bovine luteal cells to investigate the effect of LH on steroid acute regulatory protein (StAR). They reported the LH enhances the activity of StAR protein </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Rekawiecki et al., 2005)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></li>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Liu et al. investigated the effect of LH on StAR protein using rat as model and reported the positive correlation between Lh and StAR protein </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Liu et al., 2007)</span></span></span></span></li>
<li><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Eacker et al. reported that LH up regulates the StAR protein (around five fold) using mice model </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Eacker et al., 2008)</span></span></li>
</ul>
<strong>Response-response relationship</strong>
<p>Not specified</p>
<strong>Time-scale</strong>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Time scale for the response between LH to StAR protein in hours (3-20 h) </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Johnson and Bridgham, 2001; Martinat et al., 2005; Rekawiecki et al., 2005)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<strong>Known modulating factors</strong>
<p>Not specified</p>
<strong>Known Feedforward/Feedback loops influencing this KER</strong>
<p>Not specified</p>
<h4>References</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Clark, B. J., & Stocco, D. M. (1995). Expression of the steroidogenic acute regulatory (StAR) protein: a novel LH-induced mitochondrial protein required for the acute regulation of steroidogenesis in mouse Leydig tumor cells. <em>Endocr Res</em>, 21(1-2), 243-57. doi:10.3109/07435809509030440.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Eacker, S. M., Agrawal, N., Qian, K., Dichek, H. L., Gong, E. Y., Lee, K., et al. (2008). Hormonal regulation of testicular steroid and cholesterol homeostasis. <em>Mol Endocrinol</em>, 22(3), 623-35.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Johnson, A. L., & Bridgham, J. T. (2001). Regulation of steroidogenic acute regulatory protein and luteinizing hormone receptor messenger ribonucleic acid in hen granulosa cells. <em>Endocrinology</em>, 142(7), 3116-24.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Liu, T., Wimalasena, J., Bowen, R. L., & Atwood, C. S. (2007). Luteinizing hormone receptor mediates neuronal pregnenolone production via up-regulation of steroidogenic acute regulatory protein expression. <em>J Neurochem. </em>, 100(5), 1329-39.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Martinat, N., Crepieux, P., Reiter, E., & Guillou, F. (2005). Extracellular signal-regulated kinases (ERK) 1, 2 are required for luteinizing hormone (LH)-induced steroidogenesis in primary Leydig cells and control steroidogenic acute regulatory (StAR) expression. <em>Reprod Nutr Dev</em>, 45(1), 101-8. doi:10.1051/rnd:2005007.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Murayama, C., Miyazaki, H., Miyamoto, A., & Shimizu, T. (2012). Luteinizing hormone (LH) regulates production of androstenedione and progesterone via control of histone acetylation of StAR and CYP17 promoters in ovarian theca cells. <em>Mol Cell Endocrinol</em>, 350(1), 1-9. doi:S0303-7207(11)00677-0 [pii]</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">10.1016/j.mce.2011.11.014.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Rekawiecki, R., Nowik, M., & Kotwica, J. (2005). Stimulatory effect of LH, PGE2 and progesterone on StAR protein, cytochrome P450 cholesterol side chain cleavage and 3beta hydroxysteroid dehydrogenase gene expression in bovine luteal cells. <em>Prostaglandins Other Lipid Mediat</em>, 78(1-4), 169-84. doi:S1098-8823(05)00080-8 [pii]</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">10.1016/j.prostaglandins.2005.06.009.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Tsang, B. K., Armstrong, D. T., & Whitfield, J. F. (1980). Steroid biosynthesis by isolated human ovarian follicular cells in vitro. <em>J Clin Endocrinol Metab. </em>, 51(6), 1407-11.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Tsuchiya, M., Inoue, K., Matsuda, H., Nakamura, K., Mizutani, T., Miyamoto, K., et al. (2003). Expression of steroidogenic acute regulatory protein (StAR) and LH receptor in MA-10 cells. <em>Life Sciences</em>, 73(22), 2855-2863. doi:https://doi.org/10.1016/S0024-3205(03)00698-2.</span></span></span></span></p>
</div>
<div>
<h4><a href="/relationships/2582">Relationship: 2582: Increased, Steroidogenic acute regulatory protein (StAR) leads to Increased, estrogens </a></h4>
<td><a href="/aops/440">Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td>adjacent</td>
<td>High</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
</div>
<h4>Evidence Supporting Applicability of this Relationship</h4>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Steroidogenic acute regulatory (StAR) protein (37-kDa) is synthesized with a mitochondrial leader sequence in response to the cell stimulation to produce steroid and plays a crucial role in steroidogenesis </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Hanukoglu, 1992)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Research had shown in human ovary StAR protein was produced in response to the Luteinizing Hormone (LH) surge </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Kiriakidou et al., 1996)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. In particular, StAR protein involved in the transportation of the cholesterol (substrate for steroid hormone) from outer to inner mitochondrial membrane. This step is crucial and rate limiting in steroid biosynthesis. In the inner membrane of the mitochondria with the help of cleaved cholesterol pregnenolone is formed, which is the precursor to the different steroid hormones including estrogen </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(P. R. Manna et al., 2016)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Effects of StAR protein on steroidal biosynthesis had been studied by number of researchers </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Pulak R Manna et al., 2002; Pescador et al., 1996; Stocco, 2001)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Estradiol synthesis during menstrual cycle is governed via expression of StAR protein synthesis. Presence of StAR protein allows follicular production of androgens which allows the progesterone dominated microenvironment and help in sexual differentiation, growth, reproduction, development and metabolism. Kusakabe et al., had shown in trout fish (<em>Salvelinus fontinalis</em>) model that peak of StAR protein coincide with the menstrual hormone production peak </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Kusakabe et al., 2002)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Research had shown some toxic chemicals can caused alteration in steroidal regulation and resulted in the agonist effect on estrogen receptors </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Lauretta et al., 2019)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<h4>Evidence Supporting this KER</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Study on immature female rat model had shown rapid changes of the StAR protein level in the ovary during follicular development facilitate the production of estrogen </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Ronen-Fuhrmann et al., 1998)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Fang et al., had studied StAR protein expression under the influence of amphiregulin protein in cultured primary human granulosa cells collected from female. Results of the study had shown that human chorionic gonadotropin (hCG) rapidly induces amphiregulin (AREG) expression in the culture cells. Treatment with amphiregulin increase StAR expression and progesterone production in the cells </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Fang et al., 2016)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<strong>Biological Plausibility</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">StAR protein catalyzes the movement of cholesterol in the outer mitochondrial membrane to the inner membrane. There, cytochrome P450scc converts cholesterol to the steroid pregnenolone. Studies have shown (in mouse and rat model) some molecules (e.g. 25-hydroxycholesterol) can serve as a substrate for inducing the expression of StAR and influence the steroid production in different tissues. Other oxysterols molecules also capable of increasing STAR expression and pregnenolone synthesis in human endometrial stromal cells </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(P. R. Manna et al., 2016)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Increased in StAR transcripts in tissues exhibiting enhanced steroid production and increased circulating levels of 17β-estradiol and maturation inducing steroid ( 17α,20β -dihydroxy-4-pregnen-3-one).</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Acute increase in progesterone production in response to LH treatment</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Walsh et al., 2000)</span></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<strong>Uncertainties and Inconsistencies</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Chang et al., had investigated the effects of antimullerian hormone (AMH) on estradiol production in primary culture of human granulosa-lutein (hGL) cells. In the control cell estradiol concentration was found 43.2–93.7 ng/mL. Whereas,treatment with AMH (10 ng/mL) significantly reduced the estradiol accumulation in the cells </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Chang et al., 2013)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<h4>Quantitative Understanding of the Linkage</h4>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Pescador et al., had studied the StAR mRNA levels in the bovine corpus luteum. Result of the study had shown that expression of StAR mRNA was low in developing corpus luteum. In mid to late luteal phase the concentration increased 9- to 15-fold compared to the expression of StAR mRNA during developing stage. Results confirms that StAR mRNA and protein are tightly coupled in the corpus luteum cells and present at low levels during CL development and present elevated concentrations during the midluteal phase </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Pescador et al., 1996)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<strong>Response-response relationship</strong>
<p>Not specified</p>
<strong>Time-scale</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Observed for hours</span></span></p>
<strong>Known modulating factors</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Arukwe had shown nonylphenol (15 µg/L) can induce the StAR protein in juvenile Atlantic salmon (Salmo salar) fish </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Arukwe, 2005)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<strong>Known Feedforward/Feedback loops influencing this KER</strong>
<p>Not specified</p>
<h4>References</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Arukwe, A. (2005). Modulation of brain steroidogenesis by affecting transcriptional changes of steroidogenic acute regulatory (StAR) protein and cholesterol side chain cleavage (P450scc) in juvenile Atlantic salmon (Salmo salar) is a novel aspect of nonylphenol toxicity. <em>Environ Sci Technol</em>, 39(24), 9791-8. doi:10.1021/es0509937.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Chang, H. M., Klausen, C., & Leung, P. C. (2013). Antimullerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cells. <em>Fertil Steril</em>, 100(2), 585-92 e1. doi:S0015-0282(13)00515-3 [pii]</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">10.1016/j.fertnstert.2013.04.019.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Fang, L., Yu, Y., Zhang, R., He, J., & Sun, Y. P. (2016). Amphiregulin mediates hCG-induced StAR expression and progesterone production in human granulosa cells. <em>Sci Rep</em>, 6, 24917. doi:srep24917 [pii]</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">10.1038/srep24917.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Hanukoglu, I. (1992). Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis. <em>The Journal of steroid biochemistry and molecular biology</em>, 43(8), 779-804.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Johnson, A. L., Solovieva Ev Fau - Bridgham, J. T., & Bridgham, J. T. (2002). Relationship between steroidogenic acute regulatory protein expression and progesterone production in hen granulosa cells during follicle development. (0006-3363 (Print)).</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kiriakidou, M., Mcallister, J. M., Sugawara, T., & Strauss 3rd, J. (1996). Expression of steroidogenic acute regulatory protein (StAR) in the human ovary. <em>The Journal of Clinical Endocrinology & Metabolism</em>, 81(11), 4122-4128.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Kusakabe, M., Todo, T., McQuillan, H. J., Goetz, F. W., & Young, G. (2002). Characterization and expression of steroidogenic acute regulatory protein and MLN64 cDNAs in trout. <em>Endocrinology</em>, 143(6), 2062-70. doi:10.1210/endo.143.6.8672.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Lauretta, R., Sansone, A., Sansone, M., Romanelli, F., & Appetecchia, M. (2019). Endocrine Disrupting Chemicals: Effects on Endocrine Glands. <em>Front Endocrinol (Lausanne)</em>, 10, 178. doi:10.3389/fendo.2019.00178.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Manna, P. R., Dyson, M. T., Eubank, D. W., Clark, B. J., Lalli, E., Sassone-Corsi, P., et al. (2002). Regulation of steroidogenesis and the steroidogenic acute regulatory protein by a member of the cAMP response-element binding protein family. <em>Molecular Endocrinology</em>, 16(1), 184-199.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Manna, P. R., Stetson, C. L., Slominski, A. T., & Pruitt, K. (2016). Role of the steroidogenic acute regulatory protein in health and disease. <em>Endocrine</em>, 51(1), 7-21. doi:10.1007/s12020-015-0715-6</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">10.1007/s12020-015-0715-6 [pii].</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Men, Y., Fan, Y., Shen, Y., Lu, L., & Kallen, A. N. (2017). The Steroidogenic Acute Regulatory Protein (StAR) Is Regulated by the H19/let-7 Axis. <em>Endocrinology</em>, 158(2), 402-409. doi:10.1210/en.2016-1340.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Nimrod, A. (1981). On the synergistic action of androgen and FSH on progestin secretion by cultured rat granulosa cells: cellular and mitochondrial cholesterol metabolism. <em>Molecular and cellular endocrinology</em>, 21(1), 51-62.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Pescador, N., Soumano, K., Stocco, D. M., Price, C. A., & Murphy, B. D. (1996). Steroidogenic acute regulatory protein in bovine corpora lutea. <em>Biology of reproduction</em>, 55(2), 485-491.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Ronen-Fuhrmann, T., Timberg, R., King, S. R., Hales, K. H., Hales, D. B., Stocco, D. M., et al. (1998). Spatio-temporal expression patterns of steroidogenic acute regulatory protein (StAR) during follicular development in the rat ovary. <em>Endocrinology</em>, 139(1), 303-15. doi:10.1210/endo.139.1.5694.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Stocco, D. M. (2001). StAR protein and the regulation of steroid hormone biosynthesis. <em>Annu Rev Physiol. </em>, 63, 193-2013. doi:10.1146/annurev.physiol.63.1.193.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Walsh, L. P., Kuratko, C. N., & Stocco, D. M. (2000). Econazole and miconazole inhibit steroidogenesis and disrupt steroidogenic acute regulatory (StAR) protein expression post-transcriptionally. <em>J Steroid Biochem Mol Biol</em>, 75(4-5), 229-36. doi:S0960076000001709 [pii]</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">10.1016/s0960-0760(00)00170-9.</span></span></span></span></p>
<td><a href="/aops/440">Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td>adjacent</td>
<td>High</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
</div>
<h4>Evidence Supporting Applicability of this Relationship</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Judd et al, had measured the circulating estrogen level in the male and female </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">lizards (<em>Iguana iguana</em>) </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Judd et al., 1976)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Roberts et al., had estimated the circulating estrogen in the plasma collected from human volunteer </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Roberts and Szego, 1946)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Truan et al., had shown the high circulating estrogen levels in the mice model </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Truan et al., 2010)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<h4>Key Event Relationship Description</h4>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Ovaries are the principle source of estrogen hormone in premenopausal women. This estrogen functions as a circulating hormone to act on different tissues. In postmenopausal women, estrogen is produced in a number of extragonadal sites and acts locally at these sites as a paracrine or even intracrine factor. The monthly menstrual cycle in female is controlled through unique co-ordination between secreted hormones by the hypothalamus, the pituitary gland, and the ovary. Estrogen is synthesized from androgen, upon calalysis of aromatse enzyme present in the endoplasmic reticulam of the cells. Presence of aromatase enzyme is found majorly in the ovarian granulosa cells (premenopausal female), in the skin and adipose tissue (postmenopausal woman). Estrogen was synthesized in postmenopausal women due to the aromatization of steroids, found in the adipose and skin tissue.</span></span></p>
<p> </p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Aromatase is a key enzyme for estrogen formation in human tissues. In men and postmenopausal women C19 steroids undergoes aromatization in different tissues (e.g. skin, adipose) to generate estrogen. In men, testicular steroidogenesis accounts for 15% of the circulating level of estrogen. </span></span></span></span></p>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">In women, the ovarian granulosa cells are important sites of estrogen formation for local use within the ovary as well as for endocrine signalling to the target tissues (e.g. uterus, skin, breast, brain, bone). In case of postmenopausal female, ovarian aromatase expression is stopped, but estrogen level is maintained in the plasma by the increased aromatase expression in other tissues (adipose and skin). Research had shown elevated circulating estradiol may persist at sufficient levels to cause postmenopausal uterine bleeding, endometrial hyperplasia, and even cancer.</span></span></p>
<p> </p>
<h4>Evidence Supporting this KER</h4>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Steger et al., had shown the age related changes in steroid productions in the ovaries of rat model. In this work researchers had shown the elevated serum estrone and estradiol level in the rats (mid–aged) </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Steger and Peluso, 1982)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<strong>Biological Plausibility</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Estrogens in humans are classified as estrone (E1) and estradiol (E2). E2 is synthesized majorly in ovaries and testes by aromatization of testosterone. Small amounts of estrogens are produced in the adrenal glands and some peripheral tissues (e.g. skin, fat tissues). E2 and E1 are interchangeable, and both can be deactivated via hydroxylation. E2 has 1.25 to 5 times higher biological potency of E1. E2 circulates at 1.5 to 4 times more concentration of E1 in premenopausal women. E2 levels in men and postmenopausal women are much lower than in nonpregnant women. E2 levels in premenopausal women fluctuate during the menstrual cycle. An E2 level is lowest during the early follicular phase, then rise gradually until 2 to 3 days before ovulation. In the ovulatory phase E2 levels again declined.</span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Estrogens mean concentrations were higher in the females compared to males. Estradiol (258 ± 46 pg/ml), Estrone (205 ± 147 pg/ml) – In Females.</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Estradiol, 79 ± 42 pglml, Estrone, 37 ± 2 pglml – In Male </span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Assay of plasma protein fractions</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">1.5 to 2.0 µg of estriol (1.8 µg – in average) per 100 ml. of original plasma.</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Truan et al., 2010)</span></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<strong>Uncertainties and Inconsistencies</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Leung et al., had shown estradiol-17β (I mg) administration in the female rat for 3 days decrease the ovarian androgen levels (13 ± 2 pg/mg) compared to the control (34 ± 7 pg/mg). Results of the study suggest estrogen levels controlled by the negative feedback loop of testosterone production </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Leung et al., 1978)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<h4>Quantitative Understanding of the Linkage</h4>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Estrone concentrations in human</span></span></span></span></p>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Leung et al., had shown estradiol-17β (I mg) administration in the female rat for 3 days decrease the ovarian androgen levels (13 ± 2 pg/mg) compared to the control (34 ± 7 pg/mg) </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Leung et al., 1978)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<strong>Time-scale</strong>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Elevation of the circulating estrogen can be observed in days</span></span></span></span></p>
<strong>Known modulating factors</strong>
<p><span style="font-size:11pt"><span style="background-color:white"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif""><span style="color:black">Estrogen levels changes due to the following reasons.</span></span></span></span></span></span></p>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Elevations in estrogen due to aromatization</span></span></span></span></li>
<li><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Obesity with increased tissue production of E1</span></span></span></span></li>
<strong>Known Feedforward/Feedback loops influencing this KER</strong>
<p>Not specified</p>
<h4>References</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Cummings, S. R., Browner, W. S., Bauer, D., Stone, K., Ensrud, K., Jamal, S., et al. (1998). Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. <em>N Engl J Med</em>, 339(11), 733-8. doi:10.1056/NEJM199809103391104.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Elmlinger, M. W., Kuhnel, W., & Ranke, M. B. (2002). Reference ranges for serum concentrations of lutropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), cortisol and ferritin in neonates, children and young adults. <em>Clin Chem Lab Med</em>, 40(11), 1151-60. doi:10.1515/CCLM.2002.202.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Judd, H. L., Laughlin, G. A., Bacon, J. P., & Benirschke, K. (1976). Circulating androgen and estrogen concentrations in lizards (Iguana iguana). <em>Gen Comp Endocrinol</em>, 30(3), 391-5. doi:0016-6480(76)90091-5 [pii]</span></span></span></span><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">10.1016/0016-6480(76)90091-5.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Leung, P. C., Goff, A. K., Kennedy, T. G., & Armstrong, D. T. (1978). An intraovarian inhibitory action of estrogen on androgen production in vivo. <em>Biol Reprod</em>, 19(3), 641-7. doi:10.1095/biolreprod19.3.641.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Roberts, S., & Szego, C. M. (1946). The nature of circulating estrogen; lipoprotein-bound estrogen in human plasma. <em>Endocrinology</em>, 39, 183-7. doi:10.1210/endo-39-3-183.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Roy, E. J., & Wilson, M. A. (1981). Diurnal rhythm of cytoplasmic estrogen receptors in the rat brain in the absence of circulating estrogens. <em>Science</em>, 213(4515), 1525-7. doi:10.1126/science.7197053.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Steger, R. W., & Peluso, J. J. (1982). Effects of age on hormone levels and in vitro steroidogenesis by rat ovary and adrenal. <em>Exp Aging Res</em>, 8(3-4), 203-8. doi:10.1080/03610738208260367.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Truan, J. S., Chen, J. M., & Thompson, L. U. (2010). Flaxseed oil reduces the growth of human breast tumors (MCF-7) at high levels of circulating estrogen. <em>Mol Nutr Food Res</em>, 54(10), 1414-21. doi:10.1002/mnfr.200900521.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Wu, S., Zhu, Y., Zhang, J., Hu, X., & Yi, Y. (2020). [Effect of circulating estrogen level on the outcome of free fat grafting in nude mice]. <em>Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi</em>, 34(2), 220-225. doi:10.7507/1002-1892.201903011.</span></span></span></span></p>
<p style="text-align:justify"> </p>
</div>
<h3>List of Non Adjacent Key Event Relationships</h3>
<td><a href="/aops/440">Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td>non-adjacent</td>
<td>High</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>
</div>
<h4>Evidence Supporting Applicability of this Relationship</h4>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Increase in circulating estrogen level causing increase in the ovarian stromal cells observed in adult female (human) also in rabbit and rodents.</span></span></p>
<h4>Key Event Relationship Description</h4>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Hyperplasia of the ovarian epithelial cells characterized by aggregates of tubular like structures or cleft lines. In the mammalian ovary tissue presence of germ cells surrounded by the somatic cells is known as follicles. During the oestrous cycle early stage follicles either go through atresia or ovaluation to produce mature egg for fertilization. With the age ovaries run out of follicles and female undergo menopause. Repetitive rupture and repair of the epithelium tissue of the ovarian cells causes genetic aberrations causing the abnormal growth of these cells ultimately leads towards hyperplasia </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Bajwa et al., 2016)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Yamagata et al., studied that the increased estrogen were reflected in such target tissues proliferation, hyperplasia, atypical hyperplasia of the endometrium were observed in patients with ovarian tumors </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Yamagata et al., 1989)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. Goad et al., had shown that unopposed estrogen drives the endometrial hyperplasia leads towards the progression of endometrial cancer in the uterine epithelium </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Goad et al., 2018)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">. During the menstrual cycle, epithelium tissue of the ovary proliferate under the influence of higher estrogenic level, and the increased mitotic activity is likely to enhance the risk of the mutation in the cells </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Harvey A. Risch, 1998b)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<p> </p>
<h4>Evidence Supporting this KER</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Nash et al., had shown 50% increase in the growth rate of the epithelial ovarian cancer cell line (PE04) with the treatment of 17β-estradiol in vitro cell culture study </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Nash et al., 1989)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></span></span></p>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Meissner et al., had shown the endometrial hyperplasias and cancers by excessive estrogenic stimulation in the female rabbit </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Meissner et al., 1957)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<p> </p>
<strong>Biological Plausibility</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">There are many kinds of ovarian tumors that are related with the estrogen or androgen levels. Granulosa cell tumor and thecoma are well-known estrogen-producing tumors. Metastatic ovarian tumors often have androgen-producing stroma and that mucinous cystadenoma produces estrogens. Many other ovarian tumors also can produce sexual hormones in their stroma </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Tanaka et al., 2004)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Increase in concentration of estrogen</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Increase in concentration of estrogen</span></span></span></span></p>
<p style="text-align:center"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Goad et al., 2018)</span></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<strong>Uncertainties and Inconsistencies</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Ho et al., had shown that steroid hormones, primarily estrogens and progesterone, are implicated in ovarian carcinogenesis and estrogens favor neoplastic transformation of the ovarian surface epithelium </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Ho, 2003)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<h4>Quantitative Understanding of the Linkage</h4>
<p>Not specified</p>
<strong>Response-response relationship</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Vuong et al., had shown estrogen replacement therapy in the primary culture of the mouse ovarian surface epithelium cells increases the risk of ovarian cancer. Study had demonstrated that exogenous estradiol accelerates the onset of ovarian cancer in mouse models via the ESR1 pathway to result in the down-regulation of a tumour suppressor gene </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">(Vuong et al., 2017)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">.</span></span></p>
<strong>Time-scale</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Observed in months to years</span></span></p>
<strong>Known modulating factors</strong>
<p>Not specified</p>
<strong>Known Feedforward/Feedback loops influencing this KER</strong>
<p>Not specified</p>
<h4>References</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Bajwa, P., Nagendra, P., Nielsen, S., Sahoo, S., Bielanowicz, A., Lombard, J., et al. (2016). Age related increase in mTOR activity contributes to the pathological changes in ovarian surface epithelium. <em>Oncotarget</em>, 7. doi:10.18632/oncotarget.8468.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Goad, J., Ko, Y.-A., Kumar, M., Jamaluddin, M. F. B., & Tanwar, P. S. (2018). Oestrogen fuels the growth of endometrial hyperplastic lesions initiated by overactive Wnt/β-catenin signalling. <em>Carcinogenesis</em>, 39(9), 1105-1116.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Meissner, W. A., Sommers, S. C., & Sherman, G. (1957). Endometrial hyperplasia, endometrial carcinoma, and endometriosis produced experimentally by estrogen. <em>Cancer</em>, 10(3), 500-509. doi:https://doi.org/10.1002/1097-0142(195705/06)10:3<500::AID-CNCR2820100312>3.0.CO;2-V.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Mirabolghasemi, G., & Kamyab, Z. (2017). Changes of the uterine tissue in rats with polycystic ovary syndrome induced by estradiol valerate. <em>International journal of fertility & sterility</em>, 11(1), 47.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Nash, J. D., Ozols, R. F., Smyth, J. F., & Hamilton, T. C. (1989). Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. <em>Obstetrics and gynecology</em>, 73(6), 1009-1016.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Nephew, K. P., Long, X., Osborne, E., Burke, K. A., Ahluwalia, A., & Bigsby, R. M. (2000). Effect of estradiol on estrogen receptor expression in rat uterine cell types. <em>Biology of Reproduction</em>, 62(1), 168-177.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Risch, H. A. (1998a). Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. <em>Journal of the National Cancer Institute</em>, 90(23), 1774-1786.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Risch, H. A. (1998b). Hormonal Etiology of Epithelial Ovarian Cancer, With a Hypothesis Concerning the Role of Androgens and Progesterone. <em>JNCI: Journal of the National Cancer Institute</em>, 90(23), 1774-1786. doi:10.1093/jnci/90.23.1774.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Tanaka, Y. O., Tsunoda, H., Kitagawa, Y., Ueno, T., Yoshikawa, H., & Saida, Y. (2004). Functioning Ovarian Tumors: Direct and Indirect Findings at MR Imaging. <em>RadioGraphics</em>, 24(suppl_1), S147-S166. doi:10.1148/rg.24si045501.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Vuong, N. H., Salah Salah, O., & Vanderhyden, B. C. (2017). 17β-Estradiol sensitizes ovarian surface epithelium to transformation by suppressing Disabled-2 expression. <em>Scientific Reports</em>, 7(1), 16702. doi:10.1038/s41598-017-16219-2.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"Segoe UI","sans-serif"">Yamagata, S., Yamamoto, K., Tsuchida, S., Kawamura, N., Matsumoto, Y., Ueki, S., et al. (1989). Estrogen production in epithelial tumors of the ovary--clinical and endocrinological study in postmenopausal women. <em>Nihon Sanka Fujinka Gakkai zasshi</em>, 41(11), 1761-1768.</span></span></span></span></p>
<td><a href="/aops/165">Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse</a></td>
<td>non-adjacent</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td><a href="/aops/440">Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td>non-adjacent</td>
<td>High</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>
</div>
</div>
<div>
<h4><a href="/relationships/2829">Relationship: 2829: Promotion, ovarian adenomas leads to Promotion, Ovarian Cancer </a></h4>
<td><a href="/aops/440">Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia</a></td>
<td>non-adjacent</td>
<td>Moderate</td>
<td>Low</td>
</tr>
</tbody>
</table>
</div>
<h4>Evidence Supporting Applicability of this Relationship</h4>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Observed in adult female (human) also in rodents.</span></span></p>
<h4>Key Event Relationship Description</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Ovarian tumors are abnormal mass of tissues grows on or in the ovaries of the aged females. Ovarian adenomas / cystadenomas</span></span> <span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">are very common and benign type of tumors, which are found in epithelial tissues of the ovaries. Almost 60% of the ovarian tumors are due to the epithelial neoplasm (abnormal growth of tissue) of the ovary </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Limaiem et al. 2022)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Ovarian adenomas are classified into different categories such as serous cystadenoma, mucinous cystadenoma, endometrioid cystadenoma, clear cell cystadenoma and seromucinous systadenoma. Reports have shown that ovarian serous cystadenoma can turn progress to serous carcinoma </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Cheng et al. 2004)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Frequent mutations of two genes (BRAF and KRAS) are identified as the cause of the serous carcinoma.</span></span></span></span></p>
<h4>Evidence Supporting this KER</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Nishida et al., had reported the development of adenoma malignum of the uterine cervix associated with the mucinous carcinoma in a female patient </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Nishida et al. 1991)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. </span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Goedhals et al., had reported development of ovarian mucinous carcinoma arising from the mucinous cystadenoma of the ovary in a 68 yr old female patient </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Goedhals et al. 2008)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">.</span></span></span></span></p>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Smith et al., had shown with the help of immunohistochemistry the development of sebaceous adenoma arising within a benign ovarian mature cystic teratoma in a 52 yr old female patient </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Smith et al. 2011)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. </span></span></p>
<strong>Biological Plausibility</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Cheng et al., had reported the sub-classification of Ovarian adenomas / cystadenoma based on the cell types such as serous cystadenoma, mucinous cystadenoma and endometrioid cystadenoma </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Cheng et al. 2004)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Possible molecular genetic alteration associated with the high grade serous and endometrioid cystadenoma are mutation in TP53 gene and dysfunction of BRCA1 and/or BRCA 2 gene. Whereas, low grade serous carcinoma or borderline serous cystadenoma occurred via activation of the RAS-RAF signaling pathway and frequent mutations in BRAF or KRAS genes. Mucinous cystadenoma is originated in germ cells and often related with mutation in KRES gene </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Beroukhim et al. 2021)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Only 2-4% of the ovarian tumors are accounted for the endometrioid cystadenoma </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Tsukahara et al. 1982)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Endometrioid cystadenoma is related to the mutations in CTNNB1 and PTEN gene </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Bell 2005, Sanseverino et al. 2005, Wei et al. 2012)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">.</span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Increase in concentration of estrogen</span></span></span></span></p>
<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Increase in concentration of estrogen</span></span></span></span></p>
<p style="text-align:center"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Goad et al. 2018)</span></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<strong>Uncertainties and Inconsistencies</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Balat et al., had reported the detection of unthreatened late pregnancy with a large mucinous cyst adenoma of the ovary in a female patient </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Balat et al. 2002)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Vidhale et al., had reported the detection of serous cystadenoma in the ovary, which is benign in nature </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Vidhale et al. 2022)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">. Mittal, et al., had reported the detection of benign type of mucinous cystadenoma in the ovary </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Mittal et al. 2008)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">.</span></span></p>
<h4>Quantitative Understanding of the Linkage</h4>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Not enough data is available</span></span></p>
<strong>Response-response relationship</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Horn et al., had evaluated the 74 cases of borderline ovarian tumors and shown that majority of the cases are belongs to the serous borderline ovarian tumors (60.8%), followed by the mucinous borderline ovarian tumors (25.7%). Adenoma in the borderline ovarian tumors was found in 86.5% cases. The report had suggested that the association of papillary tubal hyperplasia and salpingoliths with the borderline ovarian tumors </span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">(Horn et al. 2017)</span></span><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">.</span></span></p>
<strong>Time-scale</strong>
<p><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Observed in months to years</span></span></p>
<strong>Known Feedforward/Feedback loops influencing this KER</strong>
<p>Not known</p>
<h4>References</h4>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Balat, O., Kutlar, I., Erkilic, S., Sirikci, A., Aksoy, F. and Aydin, A. (2002) Unthreatened late pregnancy with a huge mucinous cyst adenoma of the left ovary: report of an unusual case. Eur J Gynaecol Oncol 23(1), 84-85.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Bell, D.A. (2005) Origins and molecular pathology of ovarian cancer. Mod Pathol 18 Suppl 2, S19-32.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Beroukhim, G., Ozgediz, D., Cohen, P.J., Hui, P., Morotti, R., Schwartz, P.E., Yang, H. and Vash-Margita, A. (2021) Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature Review. J Pediatr Adolesc Gynecol 35(3), 359-367.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Cheng, E.J., Kurman, R.J., Wang, M., Oldt, R., Wang, B.G., Berman, D.M. and Shih, I.-M. (2004) Molecular genetic analysis of ovarian serous cystadenomas. Laboratory Investigation 84(6), 778-784.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Chodankar, R., Kwang, S., Sangiorgi, F., Hong, H., Yen, H.Y., Deng, C., Pike, M.C., Shuler, C.F., Maxson, R. and Dubeau, L. (2005) Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol 15(6), 561-565.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Dey, P., Nakayama, K., Razia, S., Ishikawa, M., Ishibashi, T., Yamashita, H., Kanno, K., Sato, S., Kiyono, T. and Kyo, S. (2022) Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells. Cancers (Basel) 14(6).</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Goad, J., Ko, Y.-A., Kumar, M., Jamaluddin, M.F.B. and Tanwar, P.S. (2018) Oestrogen fuels the growth of endometrial hyperplastic lesions initiated by overactive Wnt/β-catenin signalling. Carcinogenesis 39(9), 1105-1116.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Goedhals, J., van der Merwe, J., Yazbek, V.A. and Beukes, C.A. (2008) Adenoma malignum-like mucinous ovarian carcinoma. Histopathology 53(3), 352-354.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Horn, L.C., Angermann, K., Hentschel, B., Einenkel, J. and Hohn, A.K. (2017) Frequency of papillary tubal hyperplasia (PTH), salpingoliths and transition from adenoma to borderline ovarian tumors (BOT): A systematic analysis of 74 BOT with different histologic types. Pathol Res Pract 213(4), 305-309.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Limaiem, F., Lekkala, M.R. and Mlika, M. (2022) Ovarian Cystadenoma.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">MacDonald, P.C., Grodin, J.M., Edman, C.D., Vellios, F. and Siiteri, P.K. (1976) Origin of estrogen in a postmenopausal woman with a nonendocrine tumor of the ovary and endometrial hyperplasia. Obstet Gynecol 47(6), 644-650.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Mittal, S., Gupta, N., Sharma, A.K. and Dadhwal, V. (2008) Laparoscopic management of a large recurrent benign mucinous cystadenoma of the ovary. Arch Gynecol Obstet 277(4), 379-380.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Nishida, T., Ushijima, K., Oda, T., Sugiyama, T., Tsuji, Y., Imaishi, K. and Yakushiji, M. (1991) Minimal deviation adenocarcinoma (adenoma malignum) of the uterine cervix associated with mucinous ovarian carcinoma. Kurume Med J 38(4), 265-269.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Pascal, R.R. and Grecco, L.A. (1988) Mucinous cystadenoma of the ovary with stromal luteinization and hilar cell hyperplasia during pregnancy. Hum Pathol 19(2), 179-180.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Saloniemi, T., Lamminen, T., Huhtinen, K., Welsh, M., Saunders, P., Kujari, H. and Poutanen, M. (2007) Activation of androgens by hydroxysteroid (17beta) dehydrogenase 1 in vivo as a cause of prenatal masculinization and ovarian benign serous cystadenomas. Mol Endocrinol 21(11), 2627-2636.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Sanseverino, F., D'Andrilli, G., Petraglia, F. and Giordano, A. (2005) Molecular pathology of ovarian cancer. Anal Quant Cytol Histol 27(3), 121-124.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Smith, J., Crowe, K., McGaughran, J. and Robertson, T. (2011) Sebaceous adenoma arising within an ovarian mature cystic teratoma in Muir-Torre syndrome. Ann Diagn Pathol 16(6), 485-488.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Tsukahara, Y., Shiozawa, I., Sakai, Y., Ishii, J., Iwai, S. and Fukuta, T. (1982) Study on the histogenesis of ovarian tumors--with special reference to five clinical cases with common epithelial tumors detected during the preclinical stage. Nihon Sanka Fujinka Gakkai Zasshi 34(7), 959-965.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Vidhale, S.A., Chavarkar, S.P., Sudhamani, S. and Rao, R. (2022) Cholesterolosis of ovary associated with benign serous cystadenoma. Indian J Pathol Microbiol 65(2), 496-498.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Wei, X., Lu, Q.J., Sun, H.X., Qi, Y.F., Wang, J.O. and Cao, C.C. (2012) [Expression and significance of p-AKT, p-GSK3beta and beta-catenin in epithelial carcinoma of ovary]. Zhonghua Bing Li Xue Za Zhi 41(2), 86-90.</span></span></span></span></p>
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Segoe UI",sans-serif">Yamagata, S., Yamamoto, K., Tsuchida, S., Kawamura, N., Matsumoto, Y., Ueki, S. and Sugawa, T. (1989) Estrogen production in epithelial tumors of the ovary--clinical and endocrinological study in postmenopausal women. Nihon Sanka Fujinka Gakkai zasshi 41(11), 1761-1768.</span></span></span></span></p>